1
|
Mortier P, Vilagut G, García-Mieres H, Alayo I, Ferrer M, Amigo F, Aragonès E, Aragón-Peña A, Asúnsolo Del Barco Á, Campos M, Espuga M, González-Pinto A, Haro JM, López Fresneña N, Martínez de Salázar AD, Molina JD, Ortí-Lucas RM, Parellada M, Pelayo-Terán JM, Pérez-Gómez B, Pérez-Zapata A, Pijoan JI, Plana N, Polentinos-Castro E, Portillo-Van Diest A, Puig T, Rius C, Sanz F, Serra C, Urreta-Barallobre I, Kessler RC, Bruffaerts R, Vieta E, Pérez-Solá V, Alonso J. Health service and psychotropic medication use for mental health conditions among healthcare workers active during the Spain Covid-19 Pandemic - A prospective cohort study using web-based surveys. Psychiatry Res 2024; 334:115800. [PMID: 38387166 DOI: 10.1016/j.psychres.2024.115800] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/19/2023] [Revised: 01/30/2024] [Accepted: 02/11/2024] [Indexed: 02/24/2024]
Abstract
Little is known about healthcare workers' (HCW) use of healthcare services for mental disorders. This study presents data from a 16-month prospective cohort study of Spanish HCW (n = 4,809), recruited shortly after the COVID-19 pandemic onset, and assessed at four timepoints using web-based surveys. Use of health services among HCW with mental health conditions (i.e., those having a positive screen for mental disorders and/or suicidal thoughts and behaviours [STB]) was initially low (i.e., 18.2 %) but increased to 29.6 % at 16-month follow-up. Service use was positively associated with pre-pandemic mental health treatment (OR=1.99), a positive screen for major depressive disorder (OR=1.50), panic attacks (OR=1.74), suicidal thoughts and behaviours (OR=1.22), and experiencing severe role impairment (OR=1.33), and negatively associated with being female (OR = 0.69) and a higher daily number of work hours (OR=0.95). Around 30 % of HCW with mental health conditions used anxiolytics (benzodiazepines), especially medical doctors. Four out of ten HCW (39.0 %) with mental health conditions indicated a need for (additional) help, with most important barriers for service use being too ashamed, long waiting lists, and professional treatment not being available. Our findings delineate a clear mental health treatment gap among Spanish HCW.
Collapse
Affiliation(s)
- Philippe Mortier
- Hospital del Mar Research Institute, Barcelona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Spain.
| | - Gemma Vilagut
- Hospital del Mar Research Institute, Barcelona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Spain
| | - Helena García-Mieres
- Hospital del Mar Research Institute, Barcelona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Spain
| | - Itxaso Alayo
- Hospital del Mar Research Institute, Barcelona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Spain; Biosistemak Institute for Health Systems Research, Barakaldo, Bizkaia, Spain
| | - Montse Ferrer
- Hospital del Mar Research Institute, Barcelona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Spain; Department of Experimental and Health Sciences, Pompeu Fabra University, Barcelona, Spain
| | - Franco Amigo
- Hospital del Mar Research Institute, Barcelona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Spain
| | - Enric Aragonès
- Institut d'Investigació en Atenció Primària IDIAP Jordi Gol, Barcelona, Spain; Atenció Primària Camp de Tarragona, Institut Català de la Salut, Spain
| | - Andrés Aragón-Peña
- Epidemiology Unit, Regional Ministry of Health, Community of Madrid, Madrid, Spain; Fundación Investigación e Innovación Biosanitaria de AP, Comunidad de Madrid, Madrid, Spain
| | - Ángel Asúnsolo Del Barco
- Department of Surgery, Medical and Social Sciences, Faculty of Medicine and Health Sciences, University of Alcala, Alcalá de Henares, Spain; Ramón y Cajal Institute of Sanitary Research (IRYCIS), Madrid, Spain; Department of Epidemiology and Biostatistics, Graduate School of Public Health and Health Policy, The City University of New York, New York, NY, United States
| | - Mireia Campos
- Service of Prevention of Labor Risks, Medical Emergencies System, Generalitat de Catalunya, Spain
| | - Meritxell Espuga
- Occupational Health Service. Hospital Universitari Vall d'Hebron, Barcelona, Spain
| | - Ana González-Pinto
- BIOARABA, Hospital Universitario Araba-Santiago, UPV/EHU, Vitoria-Gasteiz, Spain; CIBER Salud Mental (CIBERSAM), Madrid, Spain
| | - Josep M Haro
- CIBER Salud Mental (CIBERSAM), Madrid, Spain; Parc Sanitari Sant Joan de Déu, Barcelona, Spain; Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
| | | | | | - Juan D Molina
- CIBER Salud Mental (CIBERSAM), Madrid, Spain; Villaverde Mental Health Center, Clinical Management Area of Psychiatry and Mental Health, Psychiatric Service, Hospital Universitario 12 de Octubre, Madrid, Spain; Research Institute Hospital 12 de Octubre (i+12), Madrid, Spain; Faculty of Health Sciences, Universidad Francisco de Vitoria, Madrid, Spain
| | - Rafael M Ortí-Lucas
- Service of Preventive Medicine and Quality of Attention, University Clinical Hospital of Valencia, Valencia, Spain
| | - Mara Parellada
- CIBER Salud Mental (CIBERSAM), Madrid, Spain; Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - José Maria Pelayo-Terán
- CIBER Salud Mental (CIBERSAM), Madrid, Spain; Servicio de Psiquiatría y Salud Mental. Hospital el Bierzo, Gerencia de Asistencia Sanitaria del Bierzo (GASBI). Gerencia Regional de Salud de Castilla y Leon (SACYL). Ponferrada, León, Spain; Area de Medicina Preventiva y Salud Pública. Universidad de León, León, Spain
| | - Beatriz Pérez-Gómez
- CIBER Epidemiología y Salud Pública (CIBERESP), Spain; National Center of Epidemiology, Instituto de Salud Carlos III (ISCIII), Madrid, Spain
| | | | - José Ignasio Pijoan
- CIBER Epidemiología y Salud Pública (CIBERESP), Spain; Clinical Epidemiology Unit-Hospital Universitario Cruces/ OSI EEC, Bilbao, Spain/ Biocruces-Bizkaia Health Research Institute, Spain
| | - Nieves Plana
- CIBER Epidemiología y Salud Pública (CIBERESP), Spain; Ramón y Cajal University Hospital, IRYCIS, Madrid, Spain
| | - Elena Polentinos-Castro
- Research Unit Primary Care Management, Madrid Health Service, Madrid, Spain; Department of Medical Specialities and Public Health. King Juan Carlos University, Madrid, Spain; Red de Investigación en Cronicidad, Atención Primaria y Promoción de la Salud RICAPPS-(RICORS). Instituto de Salud Carlos III (ISCIII), Madrid, Spain
| | - Ana Portillo-Van Diest
- Hospital del Mar Research Institute, Barcelona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Spain
| | - Teresa Puig
- Universitat Autònoma de Barcelona (UAB), Barcelona, Spain; Department of Epidemiology and Public Health, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain; CIBER Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain
| | - Cristina Rius
- CIBER Epidemiología y Salud Pública (CIBERESP), Spain; Agència de Salut Pública de Barcelona, Barcelona, Spain
| | - Ferran Sanz
- Department of Experimental and Health Sciences, Pompeu Fabra University, Barcelona, Spain; Research Progamme on Biomedical Informatics (GRIB), Hospital del Mar Research Institute, MELIS, Universitat Pompeu Fabra, Barcelona, Spain; Instituto Nacional de Bioinformatica - ELIXIR-ES, Barcelona, Spain
| | - Consol Serra
- CIBER Epidemiología y Salud Pública (CIBERESP), Spain; Institute of Neuropsychiatry and Addiction (INAD), Parc de Salut Mar, Barcelona, Spain; CiSAL-Centro de Investigación en Salud Laboral, Hospital del Mar Research Institute/UPF, Barcelona, Spain
| | - Iratxe Urreta-Barallobre
- CIBER Epidemiología y Salud Pública (CIBERESP), Spain; Osakidetza Basque Health Service, Donostialdea Integrated Health Organisation, Donostia University Hospital, Clinical Epidemiology Unit, San Sebastián, Spain; Biodonostia Health Research Institute, Clinical Epidemiology, San Sebastián, Spain
| | - Ronald C Kessler
- Department of Health Care Policy, Harvard Medical School, Boston, MA, USA
| | - Ronny Bruffaerts
- Center for Public Health Psychiatry, Universitair Psychiatrisch Centrum, KU Leuven, Leuven, Belgium
| | - Eduard Vieta
- CIBER Salud Mental (CIBERSAM), Madrid, Spain; Institute of Neuroscience, Hospital Clinic, University of Barcelona, IDIBAPS, Barcelona, Spain
| | - Víctor Pérez-Solá
- CIBER Salud Mental (CIBERSAM), Madrid, Spain; Universitat Autònoma de Barcelona (UAB), Barcelona, Spain; Institute of Neuropsychiatry and Addiction (INAD), Parc de Salut Mar, Barcelona, Spain
| | - Jordi Alonso
- Hospital del Mar Research Institute, Barcelona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Spain; Department of Experimental and Health Sciences, Pompeu Fabra University, Barcelona, Spain
| |
Collapse
|
2
|
Llop D, Feliu A, Ibarretxe D, Escribano J, Plana N, Borjabad-Rodríguez C, Masana L, Vallvé JC. Lipoprotein profile assessed by 1H NMR, BMI and blood pressure are associated with vascular alterations in children with familial hypercholesterolaemia. Nutr Metab Cardiovasc Dis 2023; 33:2035-2043. [PMID: 37543518 DOI: 10.1016/j.numecd.2023.06.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/08/2023] [Revised: 06/07/2023] [Accepted: 06/16/2023] [Indexed: 08/07/2023]
Abstract
BACKGROUND AND AIMS Children with familial hypercholesterolaemia (FH) have elevated low-density lipoprotein cholesterol (LDL-C) concentrations since birth, which increases the risk of cardiovascular disease in adulthood. Arterial injury and stiffness parameters, including carotid intima media thickness (cIMT), pulse wave velocity (PWV) and distensibility (DIST), can be detected early in childhood. We studied the associations between cIMT, PWV and DIST with the lipoprotein profile assessed by proton nuclear magnetic resonance (1H NMR) and with influential variables such as blood pressure (BP) or body mass index (BMI) in children with FH. METHODS AND RESULTS In this cross-sectional study, we included 201 children (96 with FH and 105 non-FH controls). Clinical history, physical examination and standard biochemical studies were performed. FH genetic testing was performed when clinically indicated. Carotid ultrasonography and an advanced lipoprotein profile by 1H NMR were performed. Multivariate and classification methods were used. There were no differences between cIMT, PWV and DIST between FH and non-FH children. FH children presented more total LDL and large, medium and small particles. Small LDL particles, BMI and systolic BP determined the presence of pathological IMT in the FH group. LDL size, high-density lipoproteins and very low-density lipoprotein particles together with blood pressure determined the presence of pathological arterial wall elasticity. CONCLUSIONS Alterations in lipoprotein parameters assessed by are associated with early structural and functional arterial characteristics in children with FH. BMI and BP act as boosting factors. Cardiovascular prevention should start early in children with FH, encompassing all components of a healthy lifestyle.
Collapse
Affiliation(s)
- D Llop
- Unitat de Recerca de Lípids I Arteriosclerosi, Universitat Rovira I Virgili, Reus, Catalonia, Spain; Institut D'Investigació Sanitària Pere Virgili (IISPV), Reus, Catalonia, Spain; Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas, Madrid, Spain
| | - A Feliu
- Pediatric Nutrition and Human Development Research Unit, Universitat Rovira I Virgili, IISPV, Reus, Spain
| | - D Ibarretxe
- Unitat de Recerca de Lípids I Arteriosclerosi, Universitat Rovira I Virgili, Reus, Catalonia, Spain; Institut D'Investigació Sanitària Pere Virgili (IISPV), Reus, Catalonia, Spain; Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas, Madrid, Spain; Servicio de Medicina Interna, Hospital Universitario Sant Joan, Reus, Catalonia, Spain
| | - J Escribano
- Pediatric Nutrition and Human Development Research Unit, Universitat Rovira I Virgili, IISPV, Reus, Spain
| | - N Plana
- Unitat de Recerca de Lípids I Arteriosclerosi, Universitat Rovira I Virgili, Reus, Catalonia, Spain; Institut D'Investigació Sanitària Pere Virgili (IISPV), Reus, Catalonia, Spain; Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas, Madrid, Spain; Servicio de Medicina Interna, Hospital Universitario Sant Joan, Reus, Catalonia, Spain
| | - C Borjabad-Rodríguez
- Unitat de Recerca de Lípids I Arteriosclerosi, Universitat Rovira I Virgili, Reus, Catalonia, Spain; Institut D'Investigació Sanitària Pere Virgili (IISPV), Reus, Catalonia, Spain; Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas, Madrid, Spain; Servicio de Medicina Interna, Hospital Universitario Sant Joan, Reus, Catalonia, Spain
| | - L Masana
- Unitat de Recerca de Lípids I Arteriosclerosi, Universitat Rovira I Virgili, Reus, Catalonia, Spain; Institut D'Investigació Sanitària Pere Virgili (IISPV), Reus, Catalonia, Spain; Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas, Madrid, Spain; Servicio de Medicina Interna, Hospital Universitario Sant Joan, Reus, Catalonia, Spain
| | - J C Vallvé
- Unitat de Recerca de Lípids I Arteriosclerosi, Universitat Rovira I Virgili, Reus, Catalonia, Spain; Institut D'Investigació Sanitària Pere Virgili (IISPV), Reus, Catalonia, Spain; Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas, Madrid, Spain.
| |
Collapse
|
3
|
Portillo-Van Diest A, Vilagut G, Alayo I, Ferrer M, Amigo F, Amann BL, Aragón-Peña A, Aragonès E, Asúnsolo Del Barco Á, Campos M, Del Cura-González I, Espuga M, González-Pinto A, Haro JM, Larrauri A, López-Fresneña N, Martínez de Salázar A, Molina JD, Ortí-Lucas RM, Parellada M, Pelayo-Terán JM, Pérez-Zapata A, Pijoan JI, Plana N, Puig T, Rius C, Rodríguez-Blázquez C, Sanz F, Serra C, Urreta-Barallobre I, Kessler RC, Bruffaerts R, Vieta E, Pérez-Solá V, Alonso J, Mortier P. Traumatic stress symptoms among Spanish healthcare workers during the COVID-19 pandemic: a prospective study. Epidemiol Psychiatr Sci 2023; 32:e50. [PMID: 37555258 PMCID: PMC10465320 DOI: 10.1017/s2045796023000628] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/02/2022] [Revised: 03/06/2023] [Accepted: 06/24/2023] [Indexed: 08/10/2023] Open
Abstract
AIM To investigate the occurrence of traumatic stress symptoms (TSS) among healthcare workers active during the COVID-19 pandemic and to obtain insight as to which pandemic-related stressful experiences are associated with onset and persistence of traumatic stress. METHODS This is a multicenter prospective cohort study. Spanish healthcare workers (N = 4,809) participated at an initial assessment (i.e., just after the first wave of the Spain COVID-19 pandemic) and at a 4-month follow-up assessment using web-based surveys. Logistic regression investigated associations of 19 pandemic-related stressful experiences across four domains (infection-related, work-related, health-related and financial) with TSS prevalence, incidence and persistence, including simulations of population attributable risk proportions (PARP). RESULTS Thirty-day TSS prevalence at T1 was 22.1%. Four-month incidence and persistence were 11.6% and 54.2%, respectively. Auxiliary nurses had highest rates of TSS prevalence (35.1%) and incidence (16.1%). All 19 pandemic-related stressful experiences under study were associated with TSS prevalence or incidence, especially experiences from the domains of health-related (PARP range 88.4-95.6%) and work-related stressful experiences (PARP range 76.8-86.5%). Nine stressful experiences were also associated with TSS persistence, of which having patient(s) in care who died from COVID-19 had the strongest association. This association remained significant after adjusting for co-occurring depression and anxiety. CONCLUSIONS TSSs among Spanish healthcare workers active during the COVID-19 pandemic are common and associated with various pandemic-related stressful experiences. Future research should investigate if these stressful experiences represent truly traumatic experiences and carry risk for the development of post-traumatic stress disorder.
Collapse
Affiliation(s)
- Ana Portillo-Van Diest
- Health Services Research Unit, IMIM-Institut Hospital del Mar d’Investigacions Mèdiques, Barcelona, Spain
- CIBER de Epidemiología y Salud Pública, Instituto de Salud Carlos III, Madrid, Spain
| | - Gemma Vilagut
- Health Services Research Unit, IMIM-Institut Hospital del Mar d’Investigacions Mèdiques, Barcelona, Spain
- CIBER de Epidemiología y Salud Pública, Instituto de Salud Carlos III, Madrid, Spain
| | - Itxaso Alayo
- Health Services Research Unit, IMIM-Institut Hospital del Mar d’Investigacions Mèdiques, Barcelona, Spain
- CIBER de Epidemiología y Salud Pública, Instituto de Salud Carlos III, Madrid, Spain
- Asociación instituto de investigación en sistemas de salud Biosistemak, Barakaldo, País Vasco, España
| | - Montse Ferrer
- Health Services Research Unit, IMIM-Institut Hospital del Mar d’Investigacions Mèdiques, Barcelona, Spain
- CIBER de Epidemiología y Salud Pública, Instituto de Salud Carlos III, Madrid, Spain
- Department of Medicine and Life Sciences, Universitat Pompeu Fabra, Barcelona, Spain
| | - Franco Amigo
- Health Services Research Unit, IMIM-Institut Hospital del Mar d’Investigacions Mèdiques, Barcelona, Spain
- CIBER de Epidemiología y Salud Pública, Instituto de Salud Carlos III, Madrid, Spain
| | - Benedikt L. Amann
- Department of Medicine and Life Sciences, Universitat Pompeu Fabra, Barcelona, Spain
- CIBER de Salud Mental, Instituto de Salud Carlos III, Madrid, Spain
- Centre Fórum Research Unit, Institute of Neuropsychiatry and Addictions (INAD), Parc de Salut Mar, Barcelona, Spain
- Department of Health Services Research Group, IMIM-Institut Hospital del Mar d’Investigacions Mèdiques, Barcelona, Spain
- Department for Psychiatry and Psychotherapy, Hospital of the Ludwig-Maximilians-University Munich, Germany
| | - Andrés Aragón-Peña
- Epidemiology Unit, Regional Ministry of Health, Community of Madrid, Madrid, Spain
- Fundación Investigación e Innovación Biosanitaria de AP, Comunidad de Madrid, Madrid, Spain
| | - Enric Aragonès
- Department of Atenció Primària Camp de Tarragona, Institut d’Investigació en Atenció Primària IDIAP Jordi Gol, Barcelona, Spain
- Atenció Primària Camp de Tarragona, Institut Català de la Salut, Spain
| | - Ángel Asúnsolo Del Barco
- Department of Surgery, Medical and Social Sciences, Faculty of Medicine and Health Sciences, University of Alcala, Alcalá de Henares, Spain
- Ramón y Cajal Institute of Sanitary Research (IRYCIS), Madrid, Spain
- Department of Epidemiology and Biostatistics, Graduate School of Public Health and Health Policy, The City University of New York, New York, NY, USA
| | - Mireia Campos
- Service of Prevention of Labor Risks, Medical Emergencies System, Generalitat de Catalunya, Spain
| | - Isabel Del Cura-González
- Fundación Investigación e Innovación Biosanitaria de AP, Comunidad de Madrid, Madrid, Spain
- Research Unit, Primary Care Management, Madrid Health Service, Madrid, Spain
- Department of Medical Specialities and Public Health, King Juan Carlos University, Madrid, Spain
| | - Meritxell Espuga
- Occupational Health Service, Hospital Universitari Vall d’Hebron, Barcelona, Spain
| | - Ana González-Pinto
- CIBER de Salud Mental, Instituto de Salud Carlos III, Madrid, Spain
- BIOARABA, UPV-EHU, Hospital Universitario Araba-Santiago, Vitoria-Gasteiz, Spain
| | - Josep M. Haro
- CIBER de Salud Mental, Instituto de Salud Carlos III, Madrid, Spain
- Department of Research and Development Unit, Parc Sanitari Sant Joan de Déu, Barcelona, Spain
- Department Facultat de Medicina y Ciencias de la Salut, Universitat de Barcelona (UB), Barcelona, Spain
| | - Amparo Larrauri
- National Center of Epidemiology, Instituto de Salud Carlos III, Madrid, Spain
| | - Nieves López-Fresneña
- Department Medicina Preventiva, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | | | - Juan D. Molina
- CIBER de Salud Mental, Instituto de Salud Carlos III, Madrid, Spain
- Villaverde Mental Health Center, Clinical Management Area of Psychiatry and Mental Health, Psychiatric Service, Hospital Universitario 12 de Octubre, Madrid, Spain
- Research Institute Hospital 12 de Octubre (i+12), Madrid, Spain
- Faculty of Health Sciences, Universidad Francisco de Vitoria, Madrid, Spain
| | - Rafael M. Ortí-Lucas
- Department of Preventive MedicineDepartment, Hospital Clínic Universitari, Valencia, Spain
| | - Mara Parellada
- CIBER de Salud Mental, Instituto de Salud Carlos III, Madrid, Spain
- Department Medicina Preventiva, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - José M. Pelayo-Terán
- CIBER de Salud Mental, Instituto de Salud Carlos III, Madrid, Spain
- Servicio de Psiquiatría y Salud Mental, Hospital el Bierzo, Gerencia de Asistencia Sanitaria del Bierzo (GASBI), Gerencia Regional de Salud de Castilla y Leon (SACYL), Ponferrada, León, Spain
- Area de Medicina Preventiva y Salud Pública, Universidad de León, León, Spain
| | - Aurora Pérez-Zapata
- Department Servicio de Prevención de Riesgos Laborales, Príncipe de Asturias University Hospital, Alcalá de Henares, Madrid, Spain
| | - José I. Pijoan
- CIBER de Epidemiología y Salud Pública, Instituto de Salud Carlos III, Madrid, Spain
- Department Clinical Epidemiology Unit, Hospital Universitario Cruces/OSI EEC, Bilbao, Spain
| | - Nieves Plana
- CIBER de Epidemiología y Salud Pública, Instituto de Salud Carlos III, Madrid, Spain
- Department Servicio de Prevención de Riesgos Laborales, Príncipe de Asturias University Hospital, Alcalá de Henares, Madrid, Spain
| | - Teresa Puig
- Department of Epidemiology and Public Health, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
- Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain
- Department of Paediatrics, Obstetrics and Gynaecology and Preventive Medicine and Public HealthDepartment, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
- CIBER de Enfermedades Cardiovasculares, Instituto de Salud Carlos III, Madrid, Spain
| | - Cristina Rius
- CIBER de Epidemiología y Salud Pública, Instituto de Salud Carlos III, Madrid, Spain
- Department of Medicine and Life Sciences, Universitat Pompeu Fabra, Barcelona, Spain
- Agència de Salut Pública de Barcelona, Barcelona, Spain
| | - Carmen Rodríguez-Blázquez
- National Center of Epidemiology, Instituto de Salud Carlos III, Madrid, Spain
- CIBER de Enfermedades Neurodegenerativas, Instituto de Salud Carlos III, Madrid, Spain
| | - Ferran Sanz
- Department of Medicine and Life Sciences, Universitat Pompeu Fabra, Barcelona, Spain
- Research Progamme on Biomedical Informatics (GRIB), Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain
- Instituto Nacional de Bioinformatica – ELIXIR-ES (IMPaCT-Data-ISCIII), Barcelona, Spain
| | - Consol Serra
- CIBER de Epidemiología y Salud Pública, Instituto de Salud Carlos III, Madrid, Spain
- Departament de Psiquiatria i Medicina Legal, Parc de Salut Mar PSMAR, Barcelona, Spain
- CiSAL-Centro de Investigación en Salud Laboral, IMIM/UPF, Barcelona, Spain
| | - Iratxe Urreta-Barallobre
- CIBER de Epidemiología y Salud Pública, Instituto de Salud Carlos III, Madrid, Spain
- Osakidetza Basque Health Service, Donostialdea Integrated Health Organisation, Donostia University Hospital, Clinical Epidemiology Unit, San Sebastián, Spain
- Clinical Epidemiology, Biodonostia Health Research Institute, San Sebastián, Spain
| | - Ronald C. Kessler
- Department of Health Care Policy, Harvard Medical School, Boston, MA, USA
| | - Ronny Bruffaerts
- Center for Public Health Psychiatry, Universitair Psychiatrisch Centrum, KU Leuven, Leuven, Belgium
| | - Eduard Vieta
- CIBER de Salud Mental, Instituto de Salud Carlos III, Madrid, Spain
- Hospital Clínic, Institute of Neuroscience, University of Barcelona, IDIBAPS, Barcelona, Catalonia, Spain
| | - Víctor Pérez-Solá
- CIBER de Salud Mental, Instituto de Salud Carlos III, Madrid, Spain
- Department of Paediatrics, Obstetrics and Gynaecology and Preventive Medicine and Public HealthDepartment, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
- Departament de Psiquiatria i Medicina Legal, Parc de Salut Mar PSMAR, Barcelona, Spain
| | - Jordi Alonso
- Health Services Research Unit, IMIM-Institut Hospital del Mar d’Investigacions Mèdiques, Barcelona, Spain
- CIBER de Epidemiología y Salud Pública, Instituto de Salud Carlos III, Madrid, Spain
- Department of Medicine and Life Sciences, Universitat Pompeu Fabra, Barcelona, Spain
| | - Philippe Mortier
- Health Services Research Unit, IMIM-Institut Hospital del Mar d’Investigacions Mèdiques, Barcelona, Spain
- CIBER de Epidemiología y Salud Pública, Instituto de Salud Carlos III, Madrid, Spain
| | | |
Collapse
|
4
|
Mortier P, Vilagut G, Alayo I, Ferrer M, Amigo F, Aragonès E, Aragón-Peña A, Asúnsolo del Barco A, Campos M, Espuga M, González-Pinto A, Haro J, López Fresneña N, Martínez de Salázar A, Molina J, Ortí-Lucas R, Parellada M, Pelayo-Terán J, Pérez-Gómez B, Pérez-Zapata A, Pijoan J, Plana N, Polentinos-Castro E, Portillo-Van Diest A, Puig M, Rius C, Sanz F, Serra C, Urreta-Barallobre I, Kessler R, Bruffaerts R, Vieta E, Pérez-Solá V, Alonso J, Alayo I, Alonso M, Álvarez M, Amann B, Amigo FF, Anmella G, Aragón A, Aragonés N, Aragonès E, Arizón AI, Asunsolo A, Ayora A, Ballester L, Barbas P, Basora J, Bereciartua E, Ignasi Bolibar IB, Bonfill X, Cotillas A, Cuartero A, de Paz C, Cura ID, Jesus del Yerro M, Diaz D, Domingo JL, Emparanza JI, Espallargues M, Espuga M, Estevan P, Fernandez MI, Fernandez T, Ferrer M, Ferreres Y, Fico G, Forjaz MJ, Barranco RG, Garcia TorrecillasC. Garcia-Ribera JM, Garrido A, Gil E, Gomez M, Gomez J, Pinto AG, Haro JM, Hernando M, Insigna MG, Iriberri M, Jimenez N, Jimenez X, Larrauri A, Leon F, Lopez-Fresneña N, Lopez C, Lopez-Atanes Juan Antonio Lopez-Rodriguez M, Lopez-Cortacans G, Marcos A, Martin J, Martin V, Martinez-Cortés M, Martinez-Martinez R, Martinez de Salazar AD, Martinez I, Marzola M, Mata N, Molina JM, de Dios Molina J, Molinero E, Mortier P, Muñoz C, Murru A, Olmedo J, Ortí RM, Padrós R, Pallejà M, Parra R, Pascual J, Pelayo JM, Pla R, Plana N, Aznar CP, Gomez BP, Zapata AP, Pijoan JI, Polentinos E, Puertolas B, Puig MT, Quílez A, Quintana MJ, Quiroga A, Rentero D, Rey C, Rius C, Rodriguez-Blazquez C, Rojas MJ, Romero Y, Rubio G, Rumayor M, Ruiz P, Saenz M, Sanchez J, Sanchez-Arcilla I, Sanz F, Serra C, Serra-Sutton V, Serrano M, Sola S, Solera S, Soto M, Tarrago A, Tolosa N, Vazquez M, Viciola M, Vieta E, Vilagut G, Yago S, Yañez J, Zapico Y, Zorita LM, Zorrilla I, Zurbano SL, Perez-Solá V. Four-month incidence of suicidal thoughts and behaviors among healthcare workers after the first wave of the Spain COVID-19 pandemic. J Psychiatr Res 2022; 149:10-17. [PMID: 35217315 PMCID: PMC8852847 DOI: 10.1016/j.jpsychires.2022.02.009] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/13/2021] [Revised: 02/08/2022] [Accepted: 02/14/2022] [Indexed: 12/22/2022]
Abstract
Healthcare workers (HCW) are at high risk for suicide, yet little is known about the onset of suicidal thoughts and behaviors (STB) in this important segment of the population in conjunction with the COVID-19 pandemic. We conducted a multicenter, prospective cohort study of Spanish HCW active during the COVID-9 pandemic. A total of n = 4809 HCW participated at baseline (May-September 2020; i.e., just after the first wave of the pandemic) and at a four-month follow-up assessment (October-December 2020) using web-based surveys. Logistic regression assessed the individual- and population-level associations of separate proximal (pandemic) risk factors with four-month STB incidence (i.e., 30-day STB among HCW negative for 30-day STB at baseline), each time adjusting for distal (pre-pandemic) factors. STB incidence was estimated at 4.2% (SE = 0.5; n = 1 suicide attempt). Adjusted for distal factors, proximal risk factors most strongly associated with STB incidence were various sources of interpersonal stress (scaled 0-4; odds ratio [OR] range = 1.23-1.57) followed by personal health-related stress and stress related to the health of loved ones (scaled 0-4; OR range 1.30-1.32), and the perceived lack of healthcare center preparedness (scaled 0-4; OR = 1.34). Population-attributable risk proportions for these proximal risk factors were in the range 45.3-57.6%. Other significant risk factors were financial stressors (OR range 1.26-1.81), isolation/quarantine due to COVID-19 (OR = 1.53) and having changed to a specific COVID-19 related work location (OR = 1.72). Among other interventions, our findings call for healthcare systems to implement adequate conflict communication and resolution strategies and to improve family-work balance embedded in organizational justice strategies.
Collapse
Affiliation(s)
- P. Mortier
- Health Services Research Unit, IMIM-Institut Hospital del Mar d’Investigacions Mèdiques, Barcelona, Spain,CIBER Epidemiología y Salud Pública (CIBERESP), Spain,Corresponding author. IMIM, PRBB Building. Carrer del Doctor Aiguader 88, 08003, Barcelona, Spain
| | - G. Vilagut
- Health Services Research Unit, IMIM-Institut Hospital del Mar d’Investigacions Mèdiques, Barcelona, Spain,CIBER Epidemiología y Salud Pública (CIBERESP), Spain
| | - I. Alayo
- Health Services Research Unit, IMIM-Institut Hospital del Mar d’Investigacions Mèdiques, Barcelona, Spain,CIBER Epidemiología y Salud Pública (CIBERESP), Spain
| | - M. Ferrer
- Health Services Research Unit, IMIM-Institut Hospital del Mar d’Investigacions Mèdiques, Barcelona, Spain,CIBER Epidemiología y Salud Pública (CIBERESP), Spain,Department of Experimental and Health Sciences, Pompeu Fabra University, Barcelona, Spain
| | - F. Amigo
- Health Services Research Unit, IMIM-Institut Hospital del Mar d’Investigacions Mèdiques, Barcelona, Spain,CIBER Epidemiología y Salud Pública (CIBERESP), Spain
| | - E. Aragonès
- Institut d’Investigació en Atenció Primària IDIAP Jordi Gol, Barcelona, Spain,Atenció Primària Camp de Tarragona, Institut Català de la Salut, Spain
| | - A. Aragón-Peña
- Epidemiology Unit, Regional Ministry of Health, Community of Madrid, Madrid, Spain,Fundación Investigación e Innovación Biosanitaria de AP, Comunidad de Madrid, Madrid, Spain
| | - A. Asúnsolo del Barco
- Department of Surgery, Medical and Social Sciences, Faculty of Medicine and Health Sciences, University of Alcala, Alcalá de Henares, Spain,Ramón y Cajal Institute of Sanitary Research (IRYCIS), Madrid, Spain,Department of Epidemiology and Biostatistics, Graduate School of Public Health and Health Policy, The City University of New York, New York, NY, United States
| | - M. Campos
- Service of Prevention of Labor Risks, Medical Emergencies System, Generalitat de Catalunya, Spain
| | - M. Espuga
- Occupational Health Service. Hospital Universitari Vall d’Hebron, Barcelona, Spain
| | - A. González-Pinto
- Hospital Universitario Araba-Santiago, Vitoria-Gasteiz, Spain,CIBER Salud Mental (CIBERSAM), Madrid, Spain
| | - J.M. Haro
- CIBER Salud Mental (CIBERSAM), Madrid, Spain,Parc Sanitari Sant Joan de Déu, Barcelona, Spain,Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
| | | | | | - J.D. Molina
- CIBER Salud Mental (CIBERSAM), Madrid, Spain,Villaverde Mental Health Center. Clinical Management Area of Psychiatry and Mental Health, Psychiatric Service, Hospital Universitario 12 de Octubre, Madrid, Spain,Research Institute Hospital 12 de Octubre (i+12), Madrid, Spain,Faculty of Health Sciences, Universidad Francisco de Vitoria, Madrid, Spain
| | | | - M. Parellada
- CIBER Salud Mental (CIBERSAM), Madrid, Spain,Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - J.M. Pelayo-Terán
- CIBER Salud Mental (CIBERSAM), Madrid, Spain,Servicio de Psiquiatría y Salud Mental. Hospital el Bierzo, Gerencia de Asistencia Sanitaria del Bierzo (GASBI), Gerencia Regional de Salud de Castilla y Leon (SACYL), Ponferrada, León, Spain,Area de Medicina Preventiva y Salud Pública. Universidad de León, León, Spain
| | - B. Pérez-Gómez
- CIBER Epidemiología y Salud Pública (CIBERESP), Spain,National Center of Epidemiology, Instituto de Salud Carlos III (ISCIII), Madrid, Spain
| | - A. Pérez-Zapata
- Príncipe de Asturias University Hospital, Alcalá de Henares, Madrid, Spain
| | - J.I. Pijoan
- CIBER Epidemiología y Salud Pública (CIBERESP), Spain,Hospital Universitario Cruces/ OSI EEC, Bilbao, Spain, Biocruces-Bizkaia Health Research Institute
| | - N. Plana
- CIBER Epidemiología y Salud Pública (CIBERESP), Spain,Príncipe de Asturias University Hospital, Alcalá de Henares, Madrid, Spain
| | - E. Polentinos-Castro
- Fundación Investigación e Innovación Biosanitaria de AP, Comunidad de Madrid, Madrid, Spain,Research Unit. Primary Care Management. Madrid Health Service, Madrid, Spain,Department of Medical Specialities and Public Health. King Juan Carlos University, Madrid, Spain,Health Services Research Network on Chronic Diseases (REDISSEC), Madrid, Spain
| | - A. Portillo-Van Diest
- Health Services Research Unit, IMIM-Institut Hospital del Mar d’Investigacions Mèdiques, Barcelona, Spain,CIBER Epidemiología y Salud Pública (CIBERESP), Spain
| | - M.T. Puig
- Universitat Autònoma de Barcelona (UAB), Barcelona, Spain,Department of Epidemiology and Public Health, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain,Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain,CIBER Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain
| | - C. Rius
- CIBER Epidemiología y Salud Pública (CIBERESP), Spain,Agència de Salut Pública de Barcelona, Barcelona, Spain
| | - F. Sanz
- Department of Experimental and Health Sciences, Pompeu Fabra University, Barcelona, Spain,Research Progamme on Biomedical Informatics (GRIB), Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain,Instituto Nacional de Bioinformatica - ELIXIR-ES, Barcelona, Spain
| | - C. Serra
- CIBER Epidemiología y Salud Pública (CIBERESP), Spain,Parc de Salut Mar PSMAR, Barcelona, Spain,CiSAL-Centro de Investigación en Salud Laboral, IMIM/UPF, Barcelona, Spain
| | - I. Urreta-Barallobre
- CIBER Epidemiología y Salud Pública (CIBERESP), Spain,Osakidetza Basque Health Service, Donostialdea Integrated Health Organisation, Donostia University Hospital, Clinical Epidemiology Unit, San Sebastián, Spain,Biodonostia Health Research Institute, Clinical Epidemiology, San Sebastián, Spain
| | - R.C. Kessler
- Department of Health Care Policy, Harvard Medical School, Boston, MA, USA
| | - R. Bruffaerts
- Center for Public Health Psychiatry, Universitair Psychiatrisch Centrum, KU Leuven, Leuven, Belgium
| | - E. Vieta
- CIBER Salud Mental (CIBERSAM), Madrid, Spain,Institute of Neuroscience, Hospital Clinic, University of Barcelona, IDIBAPS, Barcelona, Spain
| | - V. Pérez-Solá
- CIBER Salud Mental (CIBERSAM), Madrid, Spain,Universitat Autònoma de Barcelona (UAB), Barcelona, Spain,Parc de Salut Mar PSMAR, Barcelona, Spain
| | - J. Alonso
- Health Services Research Unit, IMIM-Institut Hospital del Mar d’Investigacions Mèdiques, Barcelona, Spain,CIBER Epidemiología y Salud Pública (CIBERESP), Spain,Department of Experimental and Health Sciences, Pompeu Fabra University, Barcelona, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Barrios V, Beato P, Brotons C, Campuzano R, Merino-Torres JF, Mostaza JM, Plana N, Rubio JA, Comellas M. Comprehensive management of risk factors in peripheral vascular disease. Expert consensus. Rev Clin Esp 2021; 222:82-90. [PMID: 34217671 DOI: 10.1016/j.rceng.2020.11.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2020] [Accepted: 11/23/2020] [Indexed: 12/24/2022]
Abstract
INTRODUCTION There is currently a degree of divergence among the main clinical practice guidelines on the management of risk factors for peripheral arterial disease (PAD). This project aims to gain understanding of the management of PAD risk factors in clinical practice and to reach a multidisciplinary consensus on the strategies to be followed in order to optimize its identification, treatment, and follow-up. METHODOLOGY A multidisciplinary consensus following the Delphi methodology. RESULTS Professionals (n = 130) with extensive experience in PAD participated in this consultation. The results suggest that in order to optimize the control of risk factors, efforts should be aimed at: (1) promoting the involvement and awareness of all specialists in the identification of and screening for the disease; (2) guaranteeing the possibility of evaluating the ankle-brachial index (ABI) in all the medical specialties involved; (3) promoting strategies for patients to quit smoking through the use of drugs, programs, or referrals to specialized units; (4) promoting an appropriate Mediterranean-based diet and the prescription of daily exercise; (5) raising awareness of the importance of ensuring LDL cholesterol values below 70 mg/dL, especially in symptomatic but also in asymptomatic patients (<55 mg/dL following the publication of the ESC/EAS guide); (6) recommending the use of antiplatelet therapy in asymptomatic patients with diabetes mellitus (DM) and/or a pathological ABI; and (7) protocolizing the annual evaluation of ABI in high-risk patients. CONCLUSION This document presents the 22 agreed-upon strategies which are intended to help professionals optimize multidisciplinary management of PAD risk factors.
Collapse
Affiliation(s)
- V Barrios
- Servicio de Cardiología, Hospital Universitario Ramón y Cajal, Universidad de Alcalá, Madrid, Spain
| | - P Beato
- Medicina Familiar y Comunitaria, Consultori Barri Cotet (Institut Català de la Salut), Premià de Dalt, Barcelona, Spain
| | - C Brotons
- Unidad de Investigación, EAP Sardenya, Instituto de Investigaciones Biomédicas Sant Pau, Barcelona, Spain
| | - R Campuzano
- Servicio de Cardiología, Unidad de Rehabilitación Cardíaca, Hospital Universitario Fundación de Alcorcón, Alcorcón, Madrid, Spain
| | - J F Merino-Torres
- Departamento de Medicina, Universidad de Valencia, Hospital Universitario La Fe e Instituto de Investigación Sanitaria La Fe, Endocrinología y Nutrición, Valencia, Spain
| | - J M Mostaza
- Servicio de Medicina Interna, Hospital Universitario La Paz-Carlos III, Madrid, Spain
| | - N Plana
- Servicio de Medicina Interna, Hospital Universitari Sant Joan-IISPV-CIBERDEM, Reus, Tarragona, Spain
| | - J A Rubio
- Servicio de Endocrinología y Nutrición, Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, Spain; Departamento de Ciencias Biomédicas, Universidad de Alcalá, Alcalá de Henares, Madrid, Spain
| | - M Comellas
- Outcomes'10, S.L., Universitat Jaume I, Castellón de la Plana, Spain.
| | | |
Collapse
|
6
|
Alonso J, Vilagut G, Mortier P, Ferrer M, Alayo I, Aragón-Peña A, Aragonès E, Campos M, Cura-González ID, Emparanza JI, Espuga M, Forjaz MJ, González-Pinto A, Haro JM, López-Fresneña N, Salázar ADMD, Molina JD, Ortí-Lucas RM, Parellada M, Pelayo-Terán JM, Pérez-Zapata A, Pijoan JI, Plana N, Puig MT, Rius C, Rodríguez-Blázquez C, Sanz F, Serra C, Kessler RC, Bruffaerts R, Vieta E, Pérez-Solà V. Mental health impact of the first wave of COVID-19 pandemic on Spanish healthcare workers: A large cross-sectional survey. Rev Psiquiatr Salud Ment (Engl Ed) 2021; 14:90-105. [PMID: 34127211 PMCID: PMC10068024 DOI: 10.1016/j.rpsmen.2021.05.003] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/28/2020] [Accepted: 12/02/2020] [Indexed: 02/05/2023]
Abstract
INTRODUCTION Healthcare workers are vulnerable to adverse mental health impacts of the COVID-19 pandemic. We assessed prevalence of mental disorders and associated factors during the first wave of the pandemic among healthcare professionals in Spain. METHODS All workers in 18 healthcare institutions (6 AACC) in Spain were invited to web-based surveys assessing individual characteristics, COVID-19 infection status and exposure, and mental health status (May 5 - September 7, 2020). We report: probable current mental disorders (Major Depressive Disorder-MDD- [PHQ-8≥10], Generalized Anxiety Disorder-GAD- [GAD-7≥10], Panic attacks, Posttraumatic Stress Disorder -PTSD- [PCL-5≥7]; and Substance Use Disorder -SUD-[CAGE-AID≥2]. Severe disability assessed by the Sheehan Disability Scale was used to identify probable "disabling" current mental disorders. RESULTS 9,138 healthcare workers participated. Prevalence of screen-positive disorder: 28.1% MDD; 22.5% GAD, 24.0% Panic; 22.2% PTSD; and 6.2% SUD. Overall 45.7% presented any current and 14.5% any disabling current mental disorder. Workers with pre-pandemic lifetime mental disorders had almost twice the prevalence than those without. Adjusting for all other variables, odds of any disabling mental disorder were: prior lifetime disorders (TUS: OR=5.74; 95%CI 2.53-13.03; Mood: OR=3.23; 95%CI:2.27-4.60; Anxiety: OR=3.03; 95%CI:2.53-3.62); age category 18-29 years (OR=1.36; 95%CI:1.02-1.82), caring "all of the time" for COVID-19 patients (OR=5.19; 95%CI: 3.61-7.46), female gender (OR=1.58; 95%CI: 1.27-1.96) and having being in quarantine or isolated (OR= 1.60; 95CI:1.31-1.95). CONCLUSIONS One in seven Spanish healthcare workers screened positive for a disabling mental disorder during the first wave of the COVID-19 pandemic. Workers reporting pre-pandemic lifetime mental disorders, those frequently exposed to COVID-19 patients, infected or quarantined/isolated, female workers, and auxiliary nurses should be considered groups in need of mental health monitoring and support.
Collapse
Affiliation(s)
- Jordi Alonso
- Health Services Research Unit, IMIM-Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Spain; Department of Experimental and Health Sciences, Pompeu Fabra University, Barcelona, Spain.
| | - Gemma Vilagut
- Health Services Research Unit, IMIM-Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Spain
| | - Philippe Mortier
- Health Services Research Unit, IMIM-Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Spain
| | - Montse Ferrer
- Health Services Research Unit, IMIM-Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Spain; Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
| | - Itxaso Alayo
- Health Services Research Unit, IMIM-Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Spain
| | - Andrés Aragón-Peña
- Epidemiology Unit, Regional Ministry of Health, Community of Madrid, Madrid, Spain; Fundación Investigación e Innovación Biosanitaria de Atención Primaria, Comunidad de Madrid, Madrid, Spain
| | - Enric Aragonès
- Institut d'Investigació en Atenció Primària IDIAP Jordi Gol, Barcelona, Spain; Atenció Primària Camp de Tarragona, Institut Català de la Salut, Spain
| | - Mireia Campos
- Service of Prevention of Labor Risks, Medical Emergencies System, Generalitat de Catalunya, Spain
| | - Isabel D Cura-González
- Research Unit, Primary Care Management, Madrid Health Service, Madrid, Spain; Department of Medical Specialities and Public Health, King Juan Carlos University, Madrid, Spain; Fundación Investigación e Innovación Biosanitaria de Atención Primaria, Comunidad de Madrid, Madrid, Spain
| | - José I Emparanza
- Hospital Universitario Donostia, San Sebastián, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Spain
| | - Meritxell Espuga
- Occupational Health Service, Hospital Universitari Vall d'Hebron, Barcelona, Spain
| | - Maria João Forjaz
- National Center of Epidemiology, Instituto de Salud Carlos III (ISCIII), Madrid, Spain; Health Services Research Network on Chronic Diseases (REDISSEC), Madrid, Spain
| | - Ana González-Pinto
- Hospital Universitario Araba-Santiago, Vitoria-Gasteiz, Spain; CIBER Salud Mental (CIBERSAM), Madrid, Spain
| | - Josep M Haro
- Universitat Autònoma de Barcelona (UAB), Barcelona, Spain; CIBER Salud Mental (CIBERSAM), Madrid, Spain; Parc Sanitari Sant Joan de Déu, Barcelona, Spain
| | | | | | - Juan D Molina
- Villaverde Mental Health Center, Clinical Management Area of Psychiatry and Mental Health, Psychiatric Service, Hospital Universitario 12 de Octubre, Madrid, Spain; Research Institute Hospital 12 de Octubre (i+12), Madrid, Spain; Faculty of Health Sciences, Francisco de Vitoria University, Madrid, Spain; CIBER Salud Mental (CIBERSAM), Madrid, Spain
| | | | - Mara Parellada
- Hospital General Universitario Gregorio Marañón, Madrid, Spain; CIBER Salud Mental (CIBERSAM), Madrid, Spain
| | | | | | - José I Pijoan
- Hospital Universitario Cruces/OSI EEC, Bilbao, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Spain
| | - Nieves Plana
- Príncipe de Asturias University Hospital, Alcalá de Henares, Madrid, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Spain
| | - Maria Teresa Puig
- Department of Epidemiology and Public Health, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain; Universitat Autònoma de Barcelona (UAB), Barcelona, Spain; CIBER Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain
| | - Cristina Rius
- Agència de Salut Pública de Barcelona, Barcelona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Spain; CIBER Salud Mental (CIBERSAM), Madrid, Spain; CIBER Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain
| | - Carmen Rodríguez-Blázquez
- National Center of Epidemiology, Instituto de Salud Carlos III (ISCIII), Madrid, Spain; CIBER Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain
| | - Ferran Sanz
- Research Progamme on Biomedical Informatics (GRIB), Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain; Department of Experimental and Health Sciences, Pompeu Fabra University, Barcelona, Spain; Instituto Nacional de Bioinformatica - ELIXIR-ES, Barcelona, Spain
| | - Consol Serra
- Parc de Salut Mar PSMAR, Barcelona, Spain; CiSAL-Centro de Investigación en Salud Laboral, IMIM/UPF, Barcelona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Spain
| | - Ronald C Kessler
- Department of Health Care Policy, Harvard Medical School, Boston, MA, USA
| | - Ronny Bruffaerts
- Center for Public Health Psychiatry, Universitair Psychiatrisch Centrum, KU Leuven, Leuven, Belgium
| | - Eduard Vieta
- Fundació Clínic per a la Recerca Biomèdica, Barcelona, Spain; CIBER Salud Mental (CIBERSAM), Madrid, Spain
| | - Víctor Pérez-Solà
- Parc de Salut Mar PSMAR, Barcelona, Spain; Universitat Autònoma de Barcelona (UAB), Barcelona, Spain; CIBER Salud Mental (CIBERSAM), Madrid, Spain
| | | |
Collapse
|
7
|
Mortier P, Vilagut G, Ferrer M, Serra C, Molina JD, López‐Fresneña N, Puig T, Pelayo‐Terán JM, Pijoan JI, Emparanza JI, Espuga M, Plana N, González‐Pinto A, Ortí‐Lucas RM, de Salázar AM, Rius C, Aragonès E, del Cura‐González I, Aragón‐Peña A, Campos M, Parellada M, Pérez‐Zapata A, Forjaz MJ, Sanz F, Haro JM, Vieta E, Pérez‐Solà V, Kessler RC, Bruffaerts R, Alonso J. Thirty-day suicidal thoughts and behaviors among hospital workers during the first wave of the Spain COVID-19 outbreak. Depress Anxiety 2021; 38:528-544. [PMID: 33393724 PMCID: PMC8246904 DOI: 10.1002/da.23129] [Citation(s) in RCA: 54] [Impact Index Per Article: 18.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/17/2020] [Revised: 11/20/2020] [Accepted: 12/05/2020] [Indexed: 11/25/2022] Open
Abstract
BACKGROUND Healthcare workers are a key occupational group at risk for suicidal thoughts and behaviors (STB). We investigated the prevalence and correlates of STB among hospital workers during the first wave of the Spain COVID-19 outbreak (March-July 2020). METHODS Data come from the baseline assessment of a cohort of Spanish hospital workers (n = 5450), recruited from 10 hospitals just after the height of the coronavirus disease 2019 (COVID-19) outbreak (May 5-July 23, 2020). Web-based self-report surveys assessed 30-day STB, individual characteristics, and potentially modifiable contextual factors related to hospital workers' work and financial situation. RESULTS Thirty-day STB prevalence was estimated at 8.4% (4.9% passive ideation only, 3.5% active ideation with or without a plan or attempt). A total of n = 6 professionals attempted suicide in the past 30 days. In adjusted models, 30-day STB remained significantly associated with pre-pandemic lifetime mood (odds ratio [OR] = 2.92) and anxiety disorder (OR = 1.90). Significant modifiable factors included a perceived lack of coordination, communication, personnel, or supervision at work (population-attributable risk proportion [PARP] = 50.5%), and financial stress (PARP = 44.1%). CONCLUSIONS AND RELEVANCE Thirty-day STB among hospital workers during the first wave of the Spain COVID-19 outbreak was high. Hospital preparedness for virus outbreaks should be increased, and strong governmental policy response is needed to increase financial security among hospital workers.
Collapse
Affiliation(s)
- Philippe Mortier
- Health Services Research UnitIMIM‐Institut Hospital del Mar d'Investigacions MèdiquesBarcelonaSpain,CIBER Epidemiología y Salud Pública (CIBERESP)MadridSpain
| | - Gemma Vilagut
- Health Services Research UnitIMIM‐Institut Hospital del Mar d'Investigacions MèdiquesBarcelonaSpain,CIBER Epidemiología y Salud Pública (CIBERESP)MadridSpain
| | - Montse Ferrer
- Health Services Research UnitIMIM‐Institut Hospital del Mar d'Investigacions MèdiquesBarcelonaSpain,CIBER Epidemiología y Salud Pública (CIBERESP)MadridSpain,Universitat Autònoma de Barcelona (UAB)BarcelonaSpain
| | - Consol Serra
- CIBER Epidemiología y Salud Pública (CIBERESP)MadridSpain,Parc de Salut Mar PSMARBarcelonaSpain,CiSAL‐Centro de Investigación en Salud LaboralIMIM/UPFBarcelonaSpain
| | - Juan D. Molina
- Villaverde Mental Health Center, Clinical Management Area of Psychiatry and Mental Health, Psychiatric ServiceHospital Universitario 12 de OctubreMadridSpain,Research Institute Hospital 12 de Octubre (i+12)MadridSpain,Faculty of Health SciencesFrancisco de Vitoria UniversityMadridSpain,CIBER Salud Mental (CIBERSAM)MadridSpain
| | | | - Teresa Puig
- Universitat Autònoma de Barcelona (UAB)BarcelonaSpain,Department of Epidemiology and Public HealthHospital de la Santa Creu i Sant PauBarcelonaSpain,Biomedical Research Institute Sant Pau (IIB Sant Pau)BarcelonaSpain,CIBER Enfermedades Cardiovasculares (CIBERCV)MadridSpain
| | | | - José I. Pijoan
- CIBER Epidemiología y Salud Pública (CIBERESP)MadridSpain,Hospital Universitario Cruces/OSI EECBilbaoSpain
| | - José I. Emparanza
- CIBER Epidemiología y Salud Pública (CIBERESP)MadridSpain,Hospital Universitario DonostiaSan SebastiánSpain
| | - Meritxell Espuga
- Occupational Health ServiceHospital Universitari Vall d'HebronBarcelonaSpain
| | - Nieves Plana
- CIBER Epidemiología y Salud Pública (CIBERESP)MadridSpain,Príncipe de Asturias University HospitalAlcalá de HenaresMadridSpain
| | - Ana González‐Pinto
- CIBER Salud Mental (CIBERSAM)MadridSpain,Hospital Universitario Araba‐SantiagoVitoria‐GasteizSpain
| | - Rafael M. Ortí‐Lucas
- CIBER Salud Mental (CIBERSAM)MadridSpain,Hospital Clínic UniversitariValenciaSpain
| | | | - Cristina Rius
- CIBER Salud Mental (CIBERSAM)MadridSpain,Agència de Salut Pública de BarcelonaBarcelonaSpain
| | - Enric Aragonès
- Institut d'Investigació en Atenció Primària IDIAP Jordi GolBarcelonaSpain,Atenció Primària Camp de TarragonaInstitut Català de la SalutTarragonaSpain
| | - Isabel del Cura‐González
- Research Unit, Primary Care ManagementMadrid Health ServiceMadridSpain,Department of Medical Specialities and Public HealthKing Juan Carlos UniversityMadridSpain,Fundación Investigación e Innovación Biosanitaria de APComunidad de MadridMadridSpain
| | - Andrés Aragón‐Peña
- Fundación Investigación e Innovación Biosanitaria de APComunidad de MadridMadridSpain,Epidemiology UnitRegional Ministry of Health, Community of MadridMadridSpain
| | - Mireia Campos
- Service of Prevention of Labor RisksMedical Emergencies System, Generalitat de CatalunyaBarcelonaSpain
| | - Mara Parellada
- CIBER Salud Mental (CIBERSAM)MadridSpain,Hospital General Universitario Gregorio MarañónMadridSpain
| | | | - Maria João Forjaz
- National Center of EpidemiologyInstituto de Salud Carlos III (ISCIII)MadridSpain,Health Services Research Network on Chronic Diseases (REDISSEC)MadridSpain
| | - Ferran Sanz
- Research Progamme on Biomedical Informatics (GRIB)Hospital del Mar Medical Research Institute (IMIM)BarcelonaSpain,Department of Experimental and Health SciencesPompeu Fabra UniversityBarcelonaSpain,Instituto Nacional de Bioinformatica—ELIXIR‐ESMadridSpain
| | - Josep M. Haro
- Universitat Autònoma de Barcelona (UAB)BarcelonaSpain,CIBER Salud Mental (CIBERSAM)MadridSpain,Parc Sanitari Sant Joan de DéuBarcelonaSpain
| | - Eduard Vieta
- CIBER Salud Mental (CIBERSAM)MadridSpain,Hospital Clínic, University of Barcelona, IDIBAPSBarcelonaSpain
| | - Víctor Pérez‐Solà
- Universitat Autònoma de Barcelona (UAB)BarcelonaSpain,Parc de Salut Mar PSMARBarcelonaSpain,CIBER Salud Mental (CIBERSAM)MadridSpain
| | - Ronald C. Kessler
- Department of Health Care PolicyHarvard Medical SchoolBostonMassachusettsUSA
| | - Ronny Bruffaerts
- Center for Public Health PsychiatryUniversitair Psychiatrisch Centrum, KU LeuvenLeuvenBelgium
| | - Jordi Alonso
- Health Services Research UnitIMIM‐Institut Hospital del Mar d'Investigacions MèdiquesBarcelonaSpain,CIBER Epidemiología y Salud Pública (CIBERESP)MadridSpain,Department of Experimental and Health SciencesPompeu Fabra UniversityBarcelonaSpain
| | | |
Collapse
|
8
|
Moreno-Vedia J, Rosales R, Heras M, Plana N, Ibarretxe D, Girona J, Masana L. Effects of HDL triglyceride enrichment on reverse cholesterol transport in dyslipidemic patients. Atherosclerosis 2020. [DOI: 10.1016/j.atherosclerosis.2020.10.205] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
9
|
Cedó L, Metso J, Santos D, Garcia-Leon A, Plana N, Sabate-Soler S, Rotllan N, Rivas-Urbina A, Méndez-Lara K, Tondo M, Heras M, Julve J, Pallarès V, Ruotsalainen AK, Levonen AL, Sanchez-Quesada J, Masana L, Kovanen P, Jauhiainen M, Lee-Rueckert M, Blanco-Vaca F, Escolà-Gil J. LDL receptor regulates the reverse transport of macrophage-derived unesterified cholesterol via concerted action of the HDL-LDL axis. Atherosclerosis 2020. [DOI: 10.1016/j.atherosclerosis.2020.10.087] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
10
|
Rodríguez-Borjabad C, Ibarretxe D, Feliu A, Ferré R, Rosell L, Gil M, Masana L, Plana N. Significant Impact Of A Lifestyle Educational Program On Children With Genetically Driven Hypercholesterolemia. Atherosclerosis 2019. [DOI: 10.1016/j.atherosclerosis.2019.06.243] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
11
|
Masana L, López-Miranda J, Civeira F, Reinares L, Maraver J, Plana N, Cuenca R, Sanchez D, Hernandez J, Andres R, Blanco A, Villamayor S. Evolocumab Is Mainly Prescribed In Fh Patients With/Without Atherosclerotic Cardiovascular Disease (Ascvd) In Lipid/Internal Medicine Units In Spain: A Retrospective, Observational Study (Retoss-Imu). Atherosclerosis 2019. [DOI: 10.1016/j.atherosclerosis.2019.06.602] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
12
|
Girona J, Rodríguez-Borjabad C, Ibarretxe D, Vallvé J, Ferré R, Heras M, Rodríguez-Calvo R, Guaita-Esteruelas S, Martínez-Micaelo N, Plana N, Masana L. Circulating Grp78/Bip Is Increased In Patients With Obesity And Related Metabolic Disorders And Is Associated With Atherosclerosis. Atherosclerosis 2019. [DOI: 10.1016/j.atherosclerosis.2019.06.402] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
13
|
Guardiola M, Oliva I, Sanchez M, Plana N, Masana L, Monk D, Ribalta J. Pcsk9 Promoter Methylation Is Associated With Small Ldl Particles In Patients With Type 2 Diabetes And Metabolic Syndrome. Atherosclerosis 2019. [DOI: 10.1016/j.atherosclerosis.2019.06.123] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
14
|
Ewer AK, Thangaratinam S, Plana N, Zamora J. Reply to Commentary on "Pulse Oximetry Screening for Critical Congenital Heart Defects". Neonatology 2019; 116:390-391. [PMID: 31454814 DOI: 10.1159/000502015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/02/2019] [Accepted: 07/05/2019] [Indexed: 11/19/2022]
Affiliation(s)
- Andrew K Ewer
- Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, United Kingdom,
| | - Shakila Thangaratinam
- Barts and the London School of Medicine and Dentistry and Queen Mary University of London, London, United Kingdom
| | - Nieves Plana
- Preventive Medicine Department, Principe de Asturias Hospital, Alcala de Henares, Spain.,Clinical Biostatistics Unit, Ramón y Cajal Hospital (IRYCIS), Madrid, Spain
| | - Javier Zamora
- Barts and the London School of Medicine and Dentistry and Queen Mary University of London, London, United Kingdom.,Clinical Biostatistics Unit, Ramón y Cajal Hospital (IRYCIS), Madrid, Spain
| |
Collapse
|
15
|
Gil serret M, Correig E, Ibarretxe D, Rodriguez D, Pardo M, Rodriguez C, Plana N, Masana L, Amigo N. Exploring lipoprotein patterns in general population with advanced 1H-NMR testing by using an unsupervised clustering approach. Atherosclerosis 2018. [DOI: 10.1016/j.atherosclerosis.2018.06.264] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
16
|
Sánchez ramos A, Casañas MartineZ M, Ibarretxe D, Tomasini R, Anglada J, Plana N, Brea A, Valdivielso P. Lysosomal acid lipase deficiency (LAL-D) : Report of new four Spanish unrelated cases. Atherosclerosis 2018. [DOI: 10.1016/j.atherosclerosis.2018.06.568] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
17
|
Escola-gil J, Cedó L, Plana N, Metso J, García-León A, Sabaté S, Heras M, Santos D, Rivas-Urbina A, Lee-Rueckert M, Sánchez-Quesada J, Kovanen P, Jauhiainen M, Masana L, Blanco-Vaca F. Defective HDL remodeling and macrophage cholesterol efflux in adult and adolescent familial hypercholesterolemic patients. Atherosclerosis 2018. [DOI: 10.1016/j.atherosclerosis.2018.06.505] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
18
|
Guardiola M, Oliva I, Plana N, Ibarretxe D, Masana L, Ribalta J. Two TAGSNPS in PCSK9 are associated with tg metabolism in patients with type 2 diabetes and metabolic syndrome. Atherosclerosis 2018. [DOI: 10.1016/j.atherosclerosis.2018.06.445] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
19
|
Girona J, Rodríguez-Borjabad C, Ibarretxe D, Heras M, Amigó N, Feliu A, Masana L, Plana N. Plasma IDOL, soluble LDLR and PCSK9 levels as potential biomarkers of familial hypercholesterolemia in children. Atherosclerosis 2018. [DOI: 10.1016/j.atherosclerosis.2018.06.051] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
20
|
Marco-Benedi V, Perez-Calahorra S, Plana N, Pedro-Botet J, Ascaso J, Lahoz C, Almagro F, Ros E, Brea A, Suarez-Tembra M, Sanchez-Hernández R, Belmonte AV, Civeira F. Cardiovascular disease in heterozygous familial hypercholesterolemia subjects on statin treatment. Atherosclerosis 2016. [DOI: 10.1016/j.atherosclerosis.2016.07.373] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
21
|
Martín-Campos J, Julve J, Plana N, Figueras R, Esteve E, Mauri M, Bueno M, Caixàs A, Llargués E, Vila À, Morales C, Soler C, Argimón J, Mayos J, Grau J, Zamora A, Matas L, Vila L, Masana L, Blanco-Vaca F. Low-density lipoprotein gene score to identify polygenic forms of familial hypercholesterolemia in a Spanish population. Atherosclerosis 2016. [DOI: 10.1016/j.atherosclerosis.2016.07.342] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
22
|
Girona J, Ibarretxe D, Plana N, Guaita S, Amigó N, Heras M, Masana L. PCSK9 circulating levels and cetp plasma activity are associated independently of lipid lowering therapies. Atherosclerosis 2016. [DOI: 10.1016/j.atherosclerosis.2016.07.157] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
23
|
Mateo-Gallego R, Perez-Calahorra S, Laclaustra M, Plana N, Lahoz C, Pedro-Botet J, Ascaso J, Belmonte AV, Valdivielso P, Brea Á, Civeira F. Two-generation cardiovascular disease prevalence in familial hypercholesterolemia. Atherosclerosis 2016. [DOI: 10.1016/j.atherosclerosis.2016.07.276] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
24
|
Sánchez-Hernández R, Stef M, Perez-Calahorra S, Almagro F, Sáenz-Aranzubía P, Plana N, Real J, Blanco-Vaca F, Ascaso J, Civeira F, Pocovi M. Characteristics of homozygous familial hypercholesterolemia in Spain. Atherosclerosis 2016. [DOI: 10.1016/j.atherosclerosis.2016.07.126] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
25
|
Merino J, Sala-Vila A, Plana N, Girona J, Vallve JC, Ibarretxe D, Ros E, Ferré R, Heras M, Masana L. Serum palmitoleate acts as a lipokine in subjects at high cardiometabolic risk. Nutr Metab Cardiovasc Dis 2016; 26:261-267. [PMID: 26817937 DOI: 10.1016/j.numecd.2015.12.008] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/27/2015] [Revised: 12/04/2015] [Accepted: 12/14/2015] [Indexed: 01/10/2023]
Abstract
BACKGROUND AND AIM Clinical data on the role as a lipokine of de novo lipogenesis-derived palmitoleic acid (C16:1n-7cis) in serum non-esterified fatty acids (palmitoleate) are scarce. We aimed to assess whether palmitoleate relates to cardiometabolic risk. METHODS AND RESULTS In this cross-sectional study we included 358 individuals aged 30-65-years at high cardiovascular risk. We tested the association of palmitoleate (determined by gas chromatography) with metabolic syndrome (MS) and its components (defined by ATPIII criteria), fatty liver index (a surrogate of non-alcoholic fatty liver disease [NAFLD]), and subclinical atherosclerosis (determined as ultrasound-measured carotid intima-media thickness and arterial stiffness). Palmitoleate concentration was higher in women compared with men (median ± range interquartile, 1.36 ± 0.96 vs. 0.97 ± 0.77 μmol/L respectively, P < 0.001). In both genders palmitoleate concentration was associated with a higher prevalence of MS: men, odds ratio [OR: 1.12 (95%CI: 1.03; 1.23, P = 0.010)]; women [OR: 1.07 (95%CI: 1.03; 1.13, P = 0.005)], and all of its components except low HDL-cholesterol and hypertriglyceridemia. Palmitoleate was also associated with increased risk of NAFLD in both men [OR: 1.12 (95%CI: 1.03; 1.29, P = 0.031)] and women [OR: 1.11 (95%CI: 1.05; 1.19, P = 0.001)]. No associations with subclinical atherosclerosis were detected. CONCLUSIONS Our observational data supports a relationship between de novo lipogenesis-derived circulating palmitoleic acid (palmitoleate) and increased cardiometabolic risk.
Collapse
Affiliation(s)
- J Merino
- Vascular Medicine and Metabolism Unit and Research Unit on Lipids and Atherosclerosis, Sant Joan University Hospital, IISPV, Rovira i Virgili University, 43201 Reus, Spain; Spanish Biomedical Research Network in Diabetes and Associated Metabolic Disorders (CIBERDEM), Barcelona, Spain.
| | - A Sala-Vila
- Lipid Clinic, Endocrinology and Nutrition Service, Biomedical Research Institute August Pi i Sunyer (IDIBAPS), Hospital Clínic, Barcelona, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Spain
| | - N Plana
- Vascular Medicine and Metabolism Unit and Research Unit on Lipids and Atherosclerosis, Sant Joan University Hospital, IISPV, Rovira i Virgili University, 43201 Reus, Spain; Spanish Biomedical Research Network in Diabetes and Associated Metabolic Disorders (CIBERDEM), Barcelona, Spain
| | - J Girona
- Vascular Medicine and Metabolism Unit and Research Unit on Lipids and Atherosclerosis, Sant Joan University Hospital, IISPV, Rovira i Virgili University, 43201 Reus, Spain; Spanish Biomedical Research Network in Diabetes and Associated Metabolic Disorders (CIBERDEM), Barcelona, Spain
| | - J C Vallve
- Vascular Medicine and Metabolism Unit and Research Unit on Lipids and Atherosclerosis, Sant Joan University Hospital, IISPV, Rovira i Virgili University, 43201 Reus, Spain; Spanish Biomedical Research Network in Diabetes and Associated Metabolic Disorders (CIBERDEM), Barcelona, Spain
| | - D Ibarretxe
- Vascular Medicine and Metabolism Unit and Research Unit on Lipids and Atherosclerosis, Sant Joan University Hospital, IISPV, Rovira i Virgili University, 43201 Reus, Spain; Spanish Biomedical Research Network in Diabetes and Associated Metabolic Disorders (CIBERDEM), Barcelona, Spain
| | - E Ros
- Lipid Clinic, Endocrinology and Nutrition Service, Biomedical Research Institute August Pi i Sunyer (IDIBAPS), Hospital Clínic, Barcelona, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Spain
| | - R Ferré
- Vascular Medicine and Metabolism Unit and Research Unit on Lipids and Atherosclerosis, Sant Joan University Hospital, IISPV, Rovira i Virgili University, 43201 Reus, Spain; Spanish Biomedical Research Network in Diabetes and Associated Metabolic Disorders (CIBERDEM), Barcelona, Spain
| | - M Heras
- Vascular Medicine and Metabolism Unit and Research Unit on Lipids and Atherosclerosis, Sant Joan University Hospital, IISPV, Rovira i Virgili University, 43201 Reus, Spain; Spanish Biomedical Research Network in Diabetes and Associated Metabolic Disorders (CIBERDEM), Barcelona, Spain
| | - L Masana
- Vascular Medicine and Metabolism Unit and Research Unit on Lipids and Atherosclerosis, Sant Joan University Hospital, IISPV, Rovira i Virgili University, 43201 Reus, Spain; Spanish Biomedical Research Network in Diabetes and Associated Metabolic Disorders (CIBERDEM), Barcelona, Spain
| |
Collapse
|
26
|
Ibarretxe D, Girona J, Plana N, Cabré A, Heras M, Ferré R, Merino J, Vallvé JC, Masana L. FABP4 plasma concentrations are determined by acquired metabolic derangements rather than genetic determinants. Nutr Metab Cardiovasc Dis 2015; 25:875-880. [PMID: 26141940 DOI: 10.1016/j.numecd.2015.05.008] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/27/2015] [Revised: 04/30/2015] [Accepted: 05/18/2015] [Indexed: 12/19/2022]
Abstract
BACKGROUND AND AIMS Circulating FABP4 is strongly associated with metabolic and cardiovascular risk (CVR) and has been proposed as a new risk biomarker. Several FABP4 gene polymorphisms have been associated with protein expression in vitro and metabolic and vascular alterations in vivo. The aim of this study is to evaluate the impact of FABP4 polymorphisms on FABP4 plasma levels and subclinical arteriosclerosis in patients with obesity, metabolic syndrome (MS) or type 2 diabetes (T2DM). METHODS AND RESULTS We studied 440 individuals with obesity, MS, T2DM or other cardiovascular risk conditions who attended the vascular medicine and metabolism unit of our hospital. Anamnesis, physical examination and anthropometry data were recorded. Standard biochemical parameters were determined. Plasma FABP4 concentrations were measured. Carotid intima-media thickness (cIMT) was assessed using ultrasonography. The following FABP4 gene single-nucleotide polymorphisms (SNPs) were analyzed: rs3834363, rs16909233, rs1054135, rs77878271, rs10808846 and rs8192688. None of the studied gene allele variants were hyper-represented in patients grouped according the presence of metabolic alterations nor were they associated with the FABP4 concentration. The FABP4 gene variants did not determine cIMT differences between the groups. In a multivariate analysis, gender and BMI, but not gene variants, significantly determined plasma FABP4 concentrations. CONCLUSIONS In clinical settings, the circulating FABP4 levels are determined by the acquired metabolic derangements and not genetic variation.
Collapse
Affiliation(s)
- D Ibarretxe
- Vascular Medicine and Metabolism Unit, Research Unit on Lipids and Atherosclerosis, "Sant Joan" University Hospital, Universitat Rovira i Virgili, IISPV, Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Reus, Spain
| | - J Girona
- Vascular Medicine and Metabolism Unit, Research Unit on Lipids and Atherosclerosis, "Sant Joan" University Hospital, Universitat Rovira i Virgili, IISPV, Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Reus, Spain
| | - N Plana
- Vascular Medicine and Metabolism Unit, Research Unit on Lipids and Atherosclerosis, "Sant Joan" University Hospital, Universitat Rovira i Virgili, IISPV, Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Reus, Spain
| | - A Cabré
- Vascular Medicine and Metabolism Unit, Research Unit on Lipids and Atherosclerosis, "Sant Joan" University Hospital, Universitat Rovira i Virgili, IISPV, Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Reus, Spain
| | - M Heras
- Vascular Medicine and Metabolism Unit, Research Unit on Lipids and Atherosclerosis, "Sant Joan" University Hospital, Universitat Rovira i Virgili, IISPV, Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Reus, Spain
| | - R Ferré
- Vascular Medicine and Metabolism Unit, Research Unit on Lipids and Atherosclerosis, "Sant Joan" University Hospital, Universitat Rovira i Virgili, IISPV, Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Reus, Spain
| | - J Merino
- Vascular Medicine and Metabolism Unit, Research Unit on Lipids and Atherosclerosis, "Sant Joan" University Hospital, Universitat Rovira i Virgili, IISPV, Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Reus, Spain
| | - J C Vallvé
- Vascular Medicine and Metabolism Unit, Research Unit on Lipids and Atherosclerosis, "Sant Joan" University Hospital, Universitat Rovira i Virgili, IISPV, Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Reus, Spain
| | - L Masana
- Vascular Medicine and Metabolism Unit, Research Unit on Lipids and Atherosclerosis, "Sant Joan" University Hospital, Universitat Rovira i Virgili, IISPV, Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Reus, Spain.
| |
Collapse
|
27
|
Ibarretxe D, Feliu A, Ferré R, Merino J, Guijarro E, Andrés P, Ramón R, Amigó E, Masana L, Plana N. Heterozygous familial hypercholesterolemia detection in children: The decopin project. Atherosclerosis 2015. [DOI: 10.1016/j.atherosclerosis.2015.04.395] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
28
|
Megias-Rangil I, Merino J, Ferré R, Plana N, Heras M, Cabré A, Bonada A, Rabassa A, Masana L. Subclinical atherosclerosis determinants in morbid obesity. Nutr Metab Cardiovasc Dis 2014; 24:963-968. [PMID: 24907020 DOI: 10.1016/j.numecd.2014.04.012] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/09/2014] [Revised: 03/31/2014] [Accepted: 04/20/2014] [Indexed: 12/30/2022]
Abstract
BACKGROUND AND AIMS Obesity is associated with increased cardiovascular risk. However, the impact of morbid obesity on vascular structure and function is not well understood. This study was designed to appraise subclinical atherosclerosis markers, including carotid intima media thickness (cIMT), endothelial function, and arterial wall stiffness, and their determinants, in morbidly obese patients. METHODS AND RESULTS In this cross-sectional study 194 overweight and obese patients were distributed in morbid-obese patients (MOP, n = 110), obese (OP, n = 84) and overweight patients (OwP, n = 33) groups. Demography, anthropometry, clinical and standard biochemical data were recorded. cIMT, endothelial function, defined as the small artery reactivity index (saRHI), and artery wall rigidity, studied by the augmentation index, were determined. More than 50% of the MOP, OP and OwP had a cIMT above the 75th percentile per age and gender. No differences in cIMT or saRHI were observed, although overweight and obese patients (OOP) had higher arterial rigidity compared with the morbid-obese patients. In a multivariate regression test, while cholesterol was the main determinant of cIMT in overweight and obese patients, glucose metabolism was the determinant in MOP. CONCLUSION More than half of the population have a cIMT above general population ranges. OwP, OP and MOP have similar cIMT and saRHI. However, OOP have greater arterial wall rigidity. Dysglycemia is the main factor associated with subclinical atherosclerosis in MOP.
Collapse
Affiliation(s)
- I Megias-Rangil
- Dietetics and Nutrition Unit, Sant Joan University Hospital, Avinguda Josep Laporte Num 1, 43204 Reus, Spain.
| | - J Merino
- Vascular Medicine and Metabolism Unit, Lipids and Atherosclerosis Research Unit, Sant Joan University Hospital, Rovira i Virgili University, IISPV, CIBERDEM. Reus, Spain
| | - R Ferré
- Vascular Medicine and Metabolism Unit, Lipids and Atherosclerosis Research Unit, Sant Joan University Hospital, Rovira i Virgili University, IISPV, CIBERDEM. Reus, Spain
| | - N Plana
- Vascular Medicine and Metabolism Unit, Lipids and Atherosclerosis Research Unit, Sant Joan University Hospital, Rovira i Virgili University, IISPV, CIBERDEM. Reus, Spain
| | - M Heras
- Vascular Medicine and Metabolism Unit, Lipids and Atherosclerosis Research Unit, Sant Joan University Hospital, Rovira i Virgili University, IISPV, CIBERDEM. Reus, Spain
| | - A Cabré
- Vascular Medicine and Metabolism Unit, Lipids and Atherosclerosis Research Unit, Sant Joan University Hospital, Rovira i Virgili University, IISPV, CIBERDEM. Reus, Spain
| | - A Bonada
- Vascular Medicine and Metabolism Unit, Lipids and Atherosclerosis Research Unit, Sant Joan University Hospital, Rovira i Virgili University, IISPV, CIBERDEM. Reus, Spain
| | - A Rabassa
- Vascular Medicine and Metabolism Unit, Lipids and Atherosclerosis Research Unit, Sant Joan University Hospital, Rovira i Virgili University, IISPV, CIBERDEM. Reus, Spain
| | - L Masana
- Vascular Medicine and Metabolism Unit, Lipids and Atherosclerosis Research Unit, Sant Joan University Hospital, Rovira i Virgili University, IISPV, CIBERDEM. Reus, Spain
| |
Collapse
|
29
|
King N, Plana N, Murthy A, Ades V. A quantitative assessment of the contraceptive decision aid Bedsider.org among low-income Spanish-speaking women in New York City. Contraception 2014. [DOI: 10.1016/j.contraception.2014.05.179] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
30
|
Plana N, King N, Ades V, Murthy A. Qualitative assessment of a contraceptive decision aid, Besider.org, among low-income Spanish-speaking women in New York City. Contraception 2014. [DOI: 10.1016/j.contraception.2014.05.180] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
31
|
Merino J, Ferré R, Girona J, Aguas D, Cabré A, Plana N, Vinuesa A, Ibarretxe D, Basora J, Buixadera C, Masana L. Physical activity below the minimum international recommendations improves oxidative stress, ADMA levels, resting heart rate and small artery endothelial function. Clin Investig Arterioscler 2014; 27:9-16. [PMID: 25112554 DOI: 10.1016/j.arteri.2014.04.004] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/14/2014] [Accepted: 04/29/2014] [Indexed: 11/28/2022]
Abstract
BACKGROUND A moderate level of physical activity (PA), such as a daily 30-min walk, reduces cardiovascular risk. There is a lack of evidence about the cardiovascular benefits of PA below this recommendation of minimum PA level. OBJECTIVE We aimed to study the impact of a lower level of PA on cardiovascular health. DESIGN Sixty-four overweight/obese men and women were enrolled in a community programme consisting of 4 months of 1h, low-intensity PA two days per week. Before and after the intervention, PA level (METs/h/wk), endogenous antioxidant status (SOD and GPX concentration and activity and oxidised LDL), ADMA concentrations, endothelial function by small artery reactive hyperaemia index (saRHI), and resting heart rate (RHR) were assessed. RESULTS After the intervention, significant increases in saRHI (P=0.031), SOD and GPX activities, and a decrease in ADMA plasma concentrations, and RHR (P<0.001 for all) were observed. Increases in PA were positively associated with increases in saRHI (r=0.341, P=0.022), GPx (r=0.303, P=0.047) and decreases in RHR (r=-0.302, P=0.047). Multivariate analyses showed that independent predictors of saRHI improvement were an increase in PA (2.65, 95%CI: 1.21-4.01), decrease in RHR (1.91, 95%CI: 1.01-4.98), and an increase in GPx (2.61, 95%CI: 1.16-5.01). CONCLUSION In obese and overweight men and women, an increase in PA, even below the minimal international recommendations, improves antioxidant capacity, RHR and peripheral small artery reactivity.
Collapse
Affiliation(s)
- J Merino
- Vascular Medicine and Metabolism Unit and Research Unit on Lipids and Atherosclerosis, Sant Joan University Hospital, IISPV, Rovira i Virgili University, Reus, Tarragona, Spain; Spanish Biomedical Research Network in Diabetes and Associated Metabolic Disorders (CIBERDEM), Barcelona, Spain.
| | - R Ferré
- Vascular Medicine and Metabolism Unit and Research Unit on Lipids and Atherosclerosis, Sant Joan University Hospital, IISPV, Rovira i Virgili University, Reus, Tarragona, Spain; Spanish Biomedical Research Network in Diabetes and Associated Metabolic Disorders (CIBERDEM), Barcelona, Spain
| | - J Girona
- Vascular Medicine and Metabolism Unit and Research Unit on Lipids and Atherosclerosis, Sant Joan University Hospital, IISPV, Rovira i Virgili University, Reus, Tarragona, Spain; Spanish Biomedical Research Network in Diabetes and Associated Metabolic Disorders (CIBERDEM), Barcelona, Spain
| | - D Aguas
- Reus Esport i Lleure, Ajuntament de Reus, Reus, Tarragona, Spain
| | - A Cabré
- Vascular Medicine and Metabolism Unit and Research Unit on Lipids and Atherosclerosis, Sant Joan University Hospital, IISPV, Rovira i Virgili University, Reus, Tarragona, Spain; Spanish Biomedical Research Network in Diabetes and Associated Metabolic Disorders (CIBERDEM), Barcelona, Spain
| | - N Plana
- Vascular Medicine and Metabolism Unit and Research Unit on Lipids and Atherosclerosis, Sant Joan University Hospital, IISPV, Rovira i Virgili University, Reus, Tarragona, Spain; Spanish Biomedical Research Network in Diabetes and Associated Metabolic Disorders (CIBERDEM), Barcelona, Spain
| | - A Vinuesa
- Atención Primaria, Institut Català de la Salut, Tarragona, Spain; Institut d'Investigació en Atenció Primària IDIAP Jordi Gol, Catalunya, Spain
| | - D Ibarretxe
- Vascular Medicine and Metabolism Unit and Research Unit on Lipids and Atherosclerosis, Sant Joan University Hospital, IISPV, Rovira i Virgili University, Reus, Tarragona, Spain; Spanish Biomedical Research Network in Diabetes and Associated Metabolic Disorders (CIBERDEM), Barcelona, Spain
| | - J Basora
- Atención Primaria, Institut Català de la Salut, Tarragona, Spain; Institut d'Investigació en Atenció Primària IDIAP Jordi Gol, Catalunya, Spain
| | - C Buixadera
- Vascular Medicine and Metabolism Unit and Research Unit on Lipids and Atherosclerosis, Sant Joan University Hospital, IISPV, Rovira i Virgili University, Reus, Tarragona, Spain; Spanish Biomedical Research Network in Diabetes and Associated Metabolic Disorders (CIBERDEM), Barcelona, Spain
| | - L Masana
- Vascular Medicine and Metabolism Unit and Research Unit on Lipids and Atherosclerosis, Sant Joan University Hospital, IISPV, Rovira i Virgili University, Reus, Tarragona, Spain; Spanish Biomedical Research Network in Diabetes and Associated Metabolic Disorders (CIBERDEM), Barcelona, Spain
| |
Collapse
|
32
|
Plana N, Figueras R, Esteve E, Mauri M, Bueno M, Caixàs A, Llargués E, Vila A, Morales C, Soler C, Argimon J, Mayos J, Grau J, Zamora A, Matas L, Vila L, Blanco-Vaca F. Use of next generation sequencing for the diagnosis of familial hypercholesterolemia. Atherosclerosis 2014. [DOI: 10.1016/j.atherosclerosis.2014.05.131] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
33
|
Oliva I, Guardiola M, Vallvé J, Ibarretxe D, Plana N, Monk D, Masana L, Ribalta J. APOA5 snps and methylation jointly contribute to the individual predisposition to hypertriglyceridemia. Atherosclerosis 2014. [DOI: 10.1016/j.atherosclerosis.2014.05.315] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
34
|
Pintó X, Valdivielso P, Perez de Juan JM, Plana N, Garcia-Arias C, Fuentes FJ, Hernández-Mijares A, Mostaza JM. Predictive factors of achieving therapeutic goals of hypertriglyceridemia. Curr Med Res Opin 2014; 30:19-26. [PMID: 24083660 DOI: 10.1185/03007995.2013.850069] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
OBJECTIVES The aim of this study was to ascertain the factors associated with non-achievement of triglyceride (TG) goals in a cohort of hypertriglyceridemic patients attending the lipid clinics of the Spanish Arteriosclerosis Society (LC-SAS). METHODS Patients with high TG levels (>2.2 mmol/L; 200 mg/dL) were included in this multicenter, prospective, observational study and followed up for 1 year. The TG goal was ≤2.2 mmol/L (200 mg/dL). Main limitations of this study are that etiologic diagnosis of hypertriglyceridemia was not done under unified criteria and drug compliance was not evaluated. RESULTS From 1394 patients initially included in the study, 929 (age range: 50 ± 12 years, 26% women) were followed up for 1 year; 523 patients (56%) failed to reach the TG target. These patients were younger, had a higher body mass index (BMI), were more frequently smokers, hypertensive and diabetic and had more severe dyslipidemia. They were also more sedentary, their diet was of poorer quality and they had higher alcohol consumption. The independent predictors of treatment failure were hypertriglyceridemia severity, low high density lipoprotein cholesterol (HDL-C), and high non-HDL-C, alcohol consumption and a raised BMI, while drug treatment had no predictive power. CONCLUSION Independent predictors of failure to achieve hypertriglyceridemia treatment goals are inappropriate lifestyle, evidenced by insufficient weight loss, alcohol consumption and dyslipidemia severity.
Collapse
Affiliation(s)
- X Pintó
- Internal Medicine Department, Hospital Universitari de Bellvitge-IDIBELL, Barcelona University , CIBERobn ISCIII , Spain
| | | | | | | | | | | | | | | |
Collapse
|
35
|
Cerecedo I, Zamora J, Fox M, Voordouw J, Plana N, Rokicka E, Fernandez-Rivas M, Vázquez Cortés S, Reche M, Fiandor A, Kowalski M, Antonides G, Mugford M, Frewer LJ, De la Hoz B. The impact of double-blind placebo- controlled food challenge (DBPCFC) on the socioeconomic cost of food allergy in Europe. J Investig Allergol Clin Immunol 2014; 24:418-424. [PMID: 25668893] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/04/2023] Open
Abstract
BACKGROUND Double-blind placebo controlled food challenge (DBPCFC) is the gold standard diagnostic test in food allergy because it minimizes diagnostic bias. OBJECTIVE To investigate the potential effect of diagnosis on the socioeconomic costs of food allergy. METHODS A prospective longitudinal cost analysis study was conducted in Spain and Poland within the EuroPrevall project. Food-allergic patients were enrolled into the study and in all cases diagnosis was confirmed through a standardized DBPCFC. Data were collected through a self-administered survey on all aspects of health and social care resource use, costs of living, and costs of leisure activities. Costs were measured before and 6 months after the DBPCFC and reported in international dollars with 2007 as the benchmark year. RESULTS Forty-two patients were enrolled. Twenty-one patients had a negative DBPCFC and the suspected food was reintroduced into their diet. Comparing total direct costs before and after the DBPCFC, the reactive group spent a significantly higher amount (median increase of $813.1 over baseline), while the tolerant group's spending decreased by a median of $87.3 (P = .031). The amount of money spent on food 6 months after diagnosis was also significantly higher in the reactive group (P = .040). Finally, a larger, but not statistically significant, decrease in total indirect costs was observed in the tolerant group compared with the reactive group ($538.3 vs $32.3). CONCLUSION DBPCFC has an impact on indirect and direct costs of living. The main contribution to this increase was money spent on food.
Collapse
|
36
|
Zamora A, Fernández de Bobadilla F, Carrion C, Vázquez G, Paluzie G, Elosua R, Vilaseca M, Martín-Urda A, Rivera A, Plana N, Masana L. Pilot study to validate a computer-based clinical decision support system for dyslipidemia treatment (HTE-DLP). Atherosclerosis 2013; 231:401-4. [DOI: 10.1016/j.atherosclerosis.2013.09.029] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/28/2013] [Revised: 09/27/2013] [Accepted: 09/28/2013] [Indexed: 11/24/2022]
|
37
|
Masana L, Cabré A, Plana N. HPS2-THRIVE results: Bad for niacin/laropiprant, good for ezetimibe? Atherosclerosis 2013; 229:449-50. [DOI: 10.1016/j.atherosclerosis.2013.06.006] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/06/2013] [Revised: 05/27/2013] [Accepted: 06/08/2013] [Indexed: 11/24/2022]
|
38
|
Olmedo E, Earl J, Guerrero C, Longo F, Alcalde R, Soria A, Grande E, Plana N, Carrato A, Garrido P. 41P IS THERE ANY ROLE FOR CIRCULATING TUMOR CELLS IN PATIENTS WITH SMALL CELL LUNG CANCER (SCLC)? Lung Cancer 2013. [DOI: 10.1016/s0169-5002(13)70262-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
39
|
Jarauta E, Mateo-Gallego R, Gilabert R, Plana N, Junyent M, de Groot E, Cenarro A, Masana L, Ros E, Civeira F. Carotid atherosclerosis and lipoprotein particle subclasses in familial hypercholesterolaemia and familial combined hyperlipidaemia. Nutr Metab Cardiovasc Dis 2012; 22:591-597. [PMID: 21196102 DOI: 10.1016/j.numecd.2010.10.011] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/14/2010] [Revised: 09/07/2010] [Accepted: 10/12/2010] [Indexed: 11/23/2022]
Abstract
BACKGROUND AND AIMS Familial hypercholesterolaemia (FH) and familial combined hyperlipidaemia (FCH) are common atherogenic disorders with great variability in cardiovascular disease (CVD). No direct atherosclerosis burden comparisons have been performed between FH and FCH in relation to lipoprotein particle distribution. METHODS AND RESULTS Risk factors and three measures of carotid intima-media thickness (IMT) in both sides were determined in 572 FH, 250 FCH and 200 controls. Lipoproteins were assessed by nuclear magnetic resonance (NMR) spectroscopy. Compared with controls, IMT measures were increased in FH and FCH. FCH had the highest adjusted mean-maximum IMT. FH had twice low-density lipoprotein (LDL) particles than controls, but similar LDL subclass size and distribution. FCH subjects also had increased LDL particles and the highest number of small LDL (1519 ± 731 nmol l(-1) vs. 887 ± 784 nmol l(-1) in FH and 545 ± 409 nmol l(-1) in controls). Age, gender, cholesterol/high-density lipoprotein (HDL) ratio, smoking and systolic blood pressure were independently associated with IMT in FH (r(2) = 0.38). The same variables, except cholesterol/HDL ratio, were associated with IMT in FCH (r(2) = 0.40). Among NMR lipoproteins, only VLDL and chylomicrons increased IMT prediction in FCH by 0.8%. CONCLUSION FH and FCH subjects show increased carotid atherosclerosis in relation to classical risk factors. Lipoprotein subclasses do not substantially contribute to IMT variability.
Collapse
Affiliation(s)
- E Jarauta
- Hospital Universitario Miguel Servet, Instituto Aragonés de Ciencias de la Salud, Avda. Isabel La Católica 1-3, Zaragoza, Spain
| | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Ferré R, Plana N, Merino J, Aragonès G, Girona J, Heras M, Coll B, Cos R, Masana L. Effects of therapeutic lifestyle changes on peripheral artery tonometry in patients with abdominal obesity. Nutr Metab Cardiovasc Dis 2012; 22:95-102. [PMID: 20708393 DOI: 10.1016/j.numecd.2010.04.008] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/29/2010] [Revised: 04/18/2010] [Accepted: 04/19/2010] [Indexed: 11/21/2022]
Abstract
BACKGROUND AND AIMS Abdominal obesity (AO) is associated with endothelial function (EF) alteration and increased global cardiovascular (CV) risk. Therapeutic lifestyle changes (TLSC) reduce CV risk, but the impact on EF assessed by peripheral artery tonometry (PAT) is unknown. In this study, we aimed to prospectively assess the effects of TLSC on EF measured by PAT in increased CV risk patients with AO. METHODS AND RESULTS 150 patients with AO and moderate CV risk were randomized to groups receiving a one-year intervention of either conventional medical care (control group, CG) or an intensive TLSC program (intervention group, IG). Vascular studies (EF by PAT, intima-media thickness (IMT)) and lifestyle (LS) assessment were performed before and after intervention. The PAT ratio improved in the IG and worsened in the CG. The global CV risk was reduced (P = 0.017) in the IG due to a significant decrease in systolic blood pressure (P < 0.001), increase in HDL cholesterol and ApolipoproteinA1 (P = 0.013). More individuals in the IG than in the CG quit smoking (P = 0.001) and increased their physical activity (P = 0.014). The improvement in at least two LS components was associated with a PAT ratio increase (2.44 IC: 95% 0.99-6.00, P = 0.051). The PAT ratio increase determined less IMT progression (-1.1 IC: 95% 0.91-1.00, P = 0.053). CONCLUSIONS Good adherence to a TLSC program reduces global CV risk and determines PAT ratio improvement. The PAT ratio increase is the main determinant of lower IMT progression.
Collapse
Affiliation(s)
- R Ferré
- Vascular Medicine and Metabolism Unit, Sant Joan University Hospital, IISPV, Universitat Rovira i Virgili, C.Sant Llorenç 21, 43201 Reus, Spain
| | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Wilson A, Gallos ID, Plana N, Lissauer D, Khan KS, Zamora J, MacArthur C, Coomarasamy A. Effectiveness of strategies incorporating training and support of traditional birth attendants on perinatal and maternal mortality: meta-analysis. BMJ 2011; 343:d7102. [PMID: 22134967 PMCID: PMC3228291 DOI: 10.1136/bmj.d7102] [Citation(s) in RCA: 60] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
OBJECTIVE To assess the effectiveness of strategies incorporating training and support of traditional birth attendants on the outcomes of perinatal, neonatal, and maternal death in developing countries. DESIGN Systematic review with meta-analysis. DATA SOURCES Medline, Embase, the Allied and Complementary Medicine database, British Nursing Index, Cochrane Library, Cumulative Index to Nursing and Allied Health Literature, BioMed Central, PsycINFO, Latin American and Caribbean Health Sciences Literature database, African Index Medicus, Web of Science, Reproductive Health Library, and Science Citation Index (from inception to April 2011), without language restrictions. Search terms were "birth attend*", "traditional midwife", "lay birth attendant", "dais", and "comadronas". Review methods We selected randomised and non-randomised controlled studies with outcomes of perinatal, neonatal, and maternal mortality. Two independent reviewers undertook data extraction. We pooled relative risks separately for the randomised and non-randomised controlled studies, using a random effects model. RESULTS We identified six cluster randomised controlled trials (n=138 549) and seven non-randomised controlled studies (n=72 225) that investigated strategies incorporating training and support of traditional birth attendants. All six randomised controlled trials found a reduction in adverse perinatal outcomes; our meta-analysis showed significant reductions in perinatal death (relative risk 0.76, 95% confidence interval 0.64 to 0.88, P<0.001; number needed to treat 35, 24 to 70) and neonatal death (0.79, 0.69 to 0.88, P<0.001; 98, 66 to 170). Meta-analysis of the non-randomised studies also showed a significant reduction in perinatal mortality (0.70, 0.57 to 0.84, p<0.001; 48, 32 to 96) and neonatal mortality (0.61, 0.48 to 0.75, P<0.001; 96, 65 to 168). Six studies reported on maternal mortality and our meta-analysis showed a non-significant reduction (three randomised trials, relative risk 0.79, 0.53 to 1.05, P=0.12; three non-randomised studies, 0.80, 0.44 to 1.15, P=0.26). CONCLUSION Perinatal and neonatal deaths are significantly reduced with strategies incorporating training and support of traditional birth attendants.
Collapse
Affiliation(s)
- Amie Wilson
- School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, UK
| | | | | | | | | | | | | | | |
Collapse
|
42
|
Aragonás G, Ferrè R, Girona J, Plana N, Merino J, Heras M, Masana L. 504 SMALL ARTERIES DILATION AND ENDOTHELIAL MARKERS IN CARDIOVASCULAR RISK PATIENTS. ATHEROSCLEROSIS SUPP 2011. [DOI: 10.1016/s1567-5688(11)70505-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
43
|
Ferré R, Merino J, Plana N, Heras M, Buixadera C, Masana L. 851 AORTIC STIFFNESS IS A DETERMINANT OF CAROTID INTIMA MEDIA THICKNESS IN PATIENTS AT INTERMEDIATE CARDIOVASCULAR RISK. ATHEROSCLEROSIS SUPP 2011. [DOI: 10.1016/s1567-5688(11)70852-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
44
|
Solanas-Barca M, Jarauta E, Martin-Fuentes P, Cofán M, Ros E, Masana L, Plana N, Cenarro A, Civeira F. 619 GENETIC VARIANTS ASSOCIATED WITH PRIMARY HYPERTRIGLYCERIDEMIA. ATHEROSCLEROSIS SUPP 2011. [DOI: 10.1016/s1567-5688(11)70620-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
45
|
De Valbuena MR, Máiz L, Gabilondo G, del Campo R, Roy G, Bayón C, Plana N, Barrio M, Girón R, Lamas A. 178* Assessment of pulmonary inflammation in cystic fibrosis patients by calprotectin determination in induced sputum. J Cyst Fibros 2011. [DOI: 10.1016/s1569-1993(11)60194-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
46
|
Ferré R, Aragonès G, Plana N, Merino J, Heras M, Coll B, Cos R, Masana L. P92 ENDOTHELIAL FUNCTION ASSESSED BY PERIPHERAL ARTERY TONOMETRY IS A DETERMINANT OF CAROTID INTIMAE-MEDIA THICKNESS REGARDLESS OF FRAMINGHAM RISK SCORE. ATHEROSCLEROSIS SUPP 2010. [DOI: 10.1016/s1567-5688(10)70159-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
47
|
Cabré A, Lázaro I, Girona J, Manzanares JM, Marimón F, Plana N, Guardiola M, Heras M, Masana L. The APOA5-1131 T>C variant enhances the association between RBP4 and hypertriglyceridemia in diabetes. Nutr Metab Cardiovasc Dis 2010; 20:243-248. [PMID: 19765959 DOI: 10.1016/j.numecd.2009.04.003] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/22/2008] [Revised: 02/19/2009] [Accepted: 04/01/2009] [Indexed: 01/11/2023]
Abstract
BACKGROUND AND AIM Type 2 diabetic patients have an increased prevalence of hypertriglyceridemia. RBP4 has been associated with insulin resistance and hypertriglyceridemia in obesity, the metabolic syndrome and type 2 diabetes. APOA5 is proposed to be a genetic modulator of triglycerides. The aim of this study was to evaluate the relationship between RBP4 plasma levels and lipid disturbances and to determine the impact of the APOA5-1131 T>C variant on this relationship in type 2 diabetic patients. METHODS AND RESULTS A total of 165 type 2 diabetic patients were included in the study. RBP4 plasma levels and the APOA5-1131 T>C variant were determined and the complete lipid profile was assessed by sequential ultracentrifugation. RBP4 was positively correlated with triglyceride levels in plasma and with all the components of triglyceride-rich lipoproteins. Despite the fact that a statistically significant relationship between the APOA5 genetic variant and RBP4 plasma levels was not found, the hypertriglyceridemic effect of high RBP4 levels was enhanced by the presence of the APOA5-1131 T>C genetic variant. Correlation coefficients were 2-fold higher for TC carriers compared to TT carriers with regard to RBP4 plasma levels and all the components of triglyceride-rich lipoproteins. Those type 2 diabetic patients with high RBP4 plasma concentrations and who were TC carriers showed an increased incidence of hypertriglyceridemia (OR=7.46, P=0.010). CONCLUSION RBP4 is associated with hypertriglyceridemia in type 2 diabetic patients. The RBP4 effect is conditioned by the presence of the APOA5-1131 T>C genetic variant.
Collapse
Affiliation(s)
- A Cabré
- CIBER of Diabetes and Associated Metabolic Diseases (CIBERDEM), URV, Department of Internal Medicine, Sant Joan University Hospital, Reus, Spain
| | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Gonzàlez M, Ribalta J, Vives G, Iftimie S, Ferré R, Plana N, Guardiola M, Dallinga-Thie G, Masana L, Castro A. Abstract: P924 NMR LIPOPROTEIN SUBCLASSES AND THE APOE GENOTYPE INFLUENCE CAROTID ATHEROSCLEROSIS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS. ATHEROSCLEROSIS SUPP 2009. [DOI: 10.1016/s1567-5688(09)71045-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
49
|
Cabre A, Lazaro I, Cofan M, Jarauta E, Plana N, Garcia-Otin A, Ascaso J, Ferre R, Civeira F, Ros E, Masana L. Abstract: P927 FABP4 PLASMA LEVELS ARE ASSOCIATED WITH THE LIPID PROFILE OF FAMILIAL COMBINED HYPERLIPIDEMIA IN THE PRESENCE OF OBESITY. ATHEROSCLEROSIS SUPP 2009. [DOI: 10.1016/s1567-5688(09)71048-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
50
|
Cabre A, Lazaro I, Girona J, Manzanares J, Marimon F, Plana N, Guardiola M, Heras M, Masana L. ADIPOSE TISSUE-DERIVED LIPOCALINS RBP4 AND FABP4 INDUCE ATHEROGENIC DYSLIPIDEMIA IN DIABETES. ATHEROSCLEROSIS SUPP 2008. [DOI: 10.1016/s1567-5688(08)70069-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|